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Abstract
Technologies that provide information about the concentrations or activities of
specific molecules in living subjects have the potential to greatly advance science and
medicine. Magnetic resonance imaging (MRI) is a tool uniquely suited to this task
because of its ability to image deep inside tissues at relatively high spatial and temporal
resolution. However, the range of molecular phenomena currently accessible to MRI is
limited by a lack of suitable molecular sensors. Most efforts to create such sensors have
focused on synthetic contrast agents, whose complicated structures make them difficult to
engineer, synthesize and deliver to target tissues. If MRI sensors could instead be made
of proteins, a number of these difficulties could be mitigated. Here, we describe two
platforms for the development of protein-based molecular sensors for MRI. The first is
based on the heme domain of the bacterial cytochrome P450-BM3, which produces
changes in TI contrast in MRI in response to small molecule binding. We developed a
high-throughput assay that allowed us to evolve this protein into a sensor of the
neurotransmitter dopamine (DA). We then used it to image DA release from cultured
cells and cocaine-induced changes in DA transport in the brains of living rats. The second
platform is based on the human iron storage protein ferritin (Ft), which enhances T2
contrast in MRI upon self-aggregation. We developed a system to express self-assembled
Ft nanoparticles incorporating multiple surface functionalities, and used it to create a
sensor for protein kinase A activity. Our results provide a proof of concept for two novel
platforms for protein-based MRI sensor development, and highlight some key advantages
of this approach over the synthetic methods used previously.
Thesis co-advisors: Alan Jasanoff, Robert Langer
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1. Background and Introduction
1.1 Molecular imaging: motivation and modalities
There is currently a growing appreciation that many biological phenomena, even
those that result in gross phenotypes or behaviors, are mediated by interactions at the
molecular level. There is therefore intense interest in the development of tools for
observing the concentrations and activities of particular biological molecules in living
specimens .
Neuroscience is a field that has placed a special emphasis on molecular sensing.
Information processing in the nervous system is largely carried out by molecular
signaling events that occur in precise spatial and temporal patterns. Historically,
molecular-level information has only been available from in vitro biochemical assays,
while spatial data came from fixed cells and tissues stained with various dyes. While this
provided crucial insights, much information was lost due to spatio-temporal decoupling
of events and measurements. More recently, molecular sensors have been developed that
enable real-time imaging of molecular events in living specimens through fluorescence,
radioactivity, or nuclear magnetic resonance.
Fluorescent reporters have been engineered to couple their fluorescent signal to
the binding of specific compounds. Fluorescent sensors have been developed for DNA
and RNA interactions, metal ions, pH, kinase activity, and various organic metabolites2 4
While these sensors often provide exquisite sensitivity and spatiotemporal resolution,
their application in biological and medical imaging is severely limited by the scattering of
light by tissues. This limitation has meant that most fluorescent sensors are only useful at
the level of cells and small tissue specimens or optically accessible parts of living
subjects (e.g. skin). This limitation is a particular problem in neuroscience since the brain
is encased in an opaque skull.
Radioactive probes work in living, opaque tissues, and allow the imaging of
molecular activity by tracking the concentration and distribution of radioactively labeled
molecules via the products their radioactive decay. For example, positron emission
tomography (PET) is often used in the clinic with 18F-fluorodeoxyglucose (FDG) to
image areas of elevated metabolic activity indicative of tumors. In these areas, a higher
than normal demand for glucose causes FDG to be locally concentrated, producing an
increase in radioactive emission. Other radioactive probes are based on receptor ligands,
and are used to monitor the expression and occupancy of their corresponding target
receptors6 . While these methods are sensitive, they have relatively low spatial resolution
(lower than 1 mm), and because their interpretation is often based on kinetic modeling,
they are best suited to studies of chronic conditions or temporal changes that occur on the
time scale of many minutes or longer. A key limitation for future development of
radioactive probes is their "always-on" operation. Radioactive decay occurs regardless of
probes' molecular environment (whereas fluorescent sensors turn on and off in response
to interactions with other molecules); thus radioactive probes cannot "sense" what is
happening at their location but merely report where they are.
Magnetic resonance imaging (MRI), which captures interactions between nuclear
spins and an applied magnetic field, has been a particularly useful tool for the imaging of
live subjects, capturing contrast produced by both endogenous tissue elements and
exogenous imaging agents. MRI is capable of providing high spatial (< 100 pim) and
temporal (AIs) resolution, and works with opaque specimens . Importantly, a variety of
mechanisms are available by which imaging agents can produce MRI contrast, making it
possible to couple the signal produced by such agents to interactions with specific
molecules of interest. MRI thus combines some of the best elements of fluorescent and
radioactive imaging. The fundamentals of MRI and MRI contrast agents are discussed in
the next section.
1.2 Magnetic resonance imaging (MRI) and MRI contrast agents
MRI is an imaging modality that interacts with the magnetic moments of nuclear
spins, typically the 1H spins of water molecules. In the presence of a strong applied
magnetic field, nuclear spins are aligned "longitudinally" - parallel to the applied field.
(Fig. 1). In a typical MRI experiment, a radio frequency electromagnetic pulse rotates
these spins 90' into the "transverse plane" where they produce a resonant signal which
serves as the readout of MRI. The contrast observed in MRI images comes primarily
from two spin relaxation mechanisms. First, transversely aligned spins that are initially in
phase with each other get dephased by local inhomogeneieties in the magnetic field in a
process called transverse or T2 relaxation, which causes spin orientations to cancel out
and leads to a loss of signal. In a second relaxation process known as longitudinal or T1
relaxation, transverse spins re-align themselves parallel to the applied magnetic field as
they dissipate their excitation energy through interactions with their local chemical
environment. MRI imaging typically captures the contrast produced by spatial variation
in either IH density or T2 or TI relaxation across a tissue specimen.
Endogenous MRI contrast produced by variation in chemical properties across
different tissues has found extensive utility in basic science and medicine. Abnormalities
in MRI images indicative of tissue damage and tumor formation are frequently used in
clinical diagnosis"' 9 . Changes in the size or contrast of particular brain regions are used to
monitor the progression of neurological disease'0 . And functional MRI (fMRI), which
takes advantage of oxygenation-dependent T2 contrast changes in hemoglobin (as
described in more detail below), has been used extensively to monitor gross activation of
different parts of the brain during mental tasks
MRI contrast can be enhanced through the use of MRI contrast agents -
magnetically active substances that typically produce image contrast by changing the TI
or T2 relaxation rates of aqueous protons (Fig. 2). For example, Gd-DTPA is an organic
chelate of gadolinium(III) that is commonly used in diagnostic MRI1". Gd3+ is strongly
paramagnetic, and its seven unpaired electrons interact with aqueous protons in a way
that enhances TI relaxation and produces an increase in signal intensity observed in TI-
weighted MRI images. Another example is superparamagnetic iron oxide (SPIO), which
comes in the form of iron oxide nanoparticles with diameters of approximately 1 Onm,
12
coated with a biocompatible organic shell . In tissues being imaged with MRI, SPIOs
produce local magnetic field inhomogeneieties which enhance T2 relaxation, causing a
decrease in signal intensity on a T2-weighted MRI image. Contrast agents have also been
developed that work through more complex mechanisms, including chemical exchange
dependent saturation transfer (CEST)13.
Several efforts have been made to create synthetic molecular sensors based on
2+_ 14
gadolinium and SPIOs . One example is a Ca -sensitive T1 agent made by Li et al . In
general, the relaxivity of T1 contrast agents depends on the ability of water molecules to
coordinate to the contrast agent's paramagnetic ion. Thus if the availability of Gd 3
coordination sites can be made to change in response to molecular interactions, it would
create a functional sensor. Li et al synthesized a molecule called DOPTA-Gd (Fig. 3a)
which features two Gd3 + chelates and a calcium-binding BAPTA group. In the presence
of calcium, the four carboxylate arms of BAPTA are occupied by calcium binding, and
the two Gd3 * ions have open coordination sites for interactions with water. When calcium
is removed, the BAPTA carboxylate groups displace the water molecules coordinated to
Gd3 *, shutting off the mechanism of MRI contrast and causing an 80% drop in relaxivity.
Functional sensors have also been made using SPIOs. In this case, a change in T2
contrast can be produced by triggered SPIO aggregation, which enhances the dephasing
effect of SPIO magnetic fields on aqueous protons. Molecular sensors based on this
mechanism have been made by functionalizing the surface of SPIOs with biomolecules
that bind to each other and cause aggregation in the presence of specific molecular
triggers. For example, Perez et al used this strategy to create sensors for specific DNA
sequences15 , while Atanasijevic et al created sensors for Ca2+ based on calcium-
dependent binding of calmodulin to M13 16 (Fig. 3b,c).
Functional sensors based on CEST have also been proposed for the measurement
of bulk environmental variables such as pH17'18
Key quantitative considerations relating to the mechanisms, design and
application of molecular sensors for MRI are covered in detail in Chapter 2.
1.3 Limitations of synthetic molecular sensors for MRI
Despite their theoretical appeal, several factors have delayed the development and
application of dynamic molecular sensors for MRI, including complexity of design,
difficulty of synthesis, and limited avenues for delivery to target biological tissues. As
described above, most existing MRI sensors comprise large, complicated organic
structures or supramolecular assemblies. Engineering such sensors usually requires
starting from scratch and iterating through painful re-synthesis of complete structures.
For example, to alter the specificity of DOPTA-Gd from calcium to another ion would
likely require replacing the BAPTA substructure with another chelate, and painstakingly
modifying the resulting structure one bond at a time to ensure proper spacing for water-
competitive interactions with Gd.
Secondly, both organic and SPIO-based sensors can be difficult to synthesize
consistently. Chelate-based sensors have intricate organic structures that require
complicated multi-step syntheses. For example, DOPTA-Gd is synthesized through 8
steps with a 0.4% total yield. SPIO-based sensors comprise supramolecular assemblies of
particles displaying multiple surface functionalities. Their performance is highly
dependent on the precise quantities of functional moieties on particle surfaces, which
impacts their avidity for each other or target molecules and their non-specific colloidal
behavior. Getting consistent functional group coverage using chemical crosslinking is an
acknowledged challenge. While many synthesis difficulties could eventually be
overcome with the standardization and controls introduced in industrial scale-up, they
continue to impede iterative sensor development and discourage researchers from making
sensors for a wider variety of imaging targets.
Finally, a major limitation for future use of synthetic MRI sensors in vivo is the
difficulty of delivering them to target cells and tissues. Sensors based on organic metal
chelates are large molecules with significant ionic charge, and SPIO-based sensors
comprise assemblies of relatively large (>30nm) particles. Getting such molecules and
assemblies to specific tissues commonly requires disruption of local tissue architecture,
and sustained or repeated imaging would necessitate repeated administration or the
engineering of special devices to prevent sensor clearance.
1.4 Basis and potential advantages of genetically engineered molecular sensors for
MRI
What if molecular sensors for MRI could be made through genetic engineering of
proteins? Protein-based sensors could be developed using well-established protein
engineering methods. They could be synthesized easily in cultured cells. And they could
be applied in vivo by direct delivery or in-situ synthesis in cells targeted with
corresponding genetic constructs. They could thus potentially overcome some of the
aforementioned challenges facing synthetic sensors.
To create MRI sensors based on proteins, one could take advantage of the
magnetic properties of naturally occurring metalloproteins, which contain paramagnetic
ions that can interact with water molecules to accelerate nuclear magnetic T1 or T2
relaxation rates and thus produce MRI contrast. Many classes of proteins contain metal
elements which serve as enhancers of binding, catalysis or electron transfer.
In fact, an important precedent for protein-based MRI sensors already exists in the
form of hemoglobin (Hb), the protein responsible for oxygen transport in blood. Each of
Hb's four subunits houses a heme-coordinated iron(II) atom that has one coordination site
available for the binding of 02 (Fig. 4), the occupancy of which depends on local 02
19 2+
concentration19 . In its deoxy state, Hb's Fe ions have unpaired electrons, making the
protein paramagnetic and causing it to produce T2 contrast in MRI. When oxygen is
bound, Fe2+ electrons transition to a paired state, eliminating the protein's paramagnetism
and T2 contrast. As a result, Hb functions as an MRI sensor of oxygen. This property of
Hb forms the basis of fMRI, where it enables the observation of locally elevated
metabolic activity in the brain during mental tasks20.
If other proteins like Hb can be identified or created to sense various molecular
targets, the resulting protein-based sensors could have three important advantages over
synthetic sensors. First, their design and modification could be aided by the use of
established protein engineering approaches, including rational mutagenesis,
recombination and directed evolution. These approaches have been used successfully to
create proteins for a variety of purposes, including protein-based fluorescent sensing,
enzymatic catalysts, receptor binding and organization of inorganic materials. One
advantage of these methods is the ease and low cost with which proteins' specificity can
be altered. In the context of MRI sensors, this could mean that an imaging agent that
senses one molecule could be modified to sense another without having to design an
entirely new sensor from scratch.
A second potential advantage of protein-based MRI sensors could be ease of
synthesis. Many expression systems ranging from bacteria to whole animals exist that can
make proteins after transfection with the corresponding DNA. For each sensor, an
appropriate system can be chosen based on codon compatibility, post-translational
modifications and requirements for co-expression with other proteins. Once an
expression system is established for a given sensor, derivatives of this sensor can likely
use the same system.
Finally, a potential long-term advantage of genetically engineered molecular
sensors is the number of delivery options they make available for in-vivo use. Both
synthetic sensors and purified protein-based sensors could be delivered to target tissues in
their intact form. But unlike synthetic sensors, protein-based sensors could also
potentially be delivered to target cells as genes. This would allow them to take advantage
of existing and future gene delivery methods, including viral and non-viral vectors. Genes
could be delivered in-situ to their target tissues, or could be pre-inserted into cells (such
as stem cells) destined for implantation.
1.5 Two protein platforms for the development of genetically engineered molecular
sensors for MRI
This thesis explores two protein platforms for developing genetically engineered
molecular sensors for MRI. Both platforms are based on naturally occurring
metalloproteins that produce MRI contrast. They differ in the their contrast mechanisms
(Tl vs T2), the protein engineering methods employed in modifying them to sense
specific molecular targets, and the targets chosen in each case.
The first platform is based on the cytochrome P450-BM3, a water-soluble fatty
acid monooxygenase from Bacillus megaterium (BM3). The wild-type BM3 enzyme is a
soluble fatty acid hydroxylase comprising a 53 kDa heme domain fused to a 65 kDa
reductase domain. The heme domain (BM3h) contains a single paramagnetic iron(III)
atom (mixed spin 1/2 and 5/222), bound to a hemin prosthetic and axially coordinated by
residue C399 on the protein. In the absence of substrate, the remaining iron coordination
site is filled by a water molecule. Interaction between exchanging water molecules at
24the axial site and the heme iron atom promotes TI relaxation in aqueous solutions . In a
manner similar to DOPTA-Gd, the binding of BM3's native substrates (long-chain fatty
acids) at the paramagnetic Fe3+ displaces water molecules and reduces the TI effect,
making BM3h a candidate molecular sensor. To create a sensor for interesting small
molecules (for example, neurotransmitters), the binding specificity BM3h would have to
be tuned away from it native substrates to the specific molecules of interest.
Conveniently, the ability to tune substrate binding in BM3h has already been
demonstrated by Frances Arnold and colleagues, who used directed evolution to create
BM3h-based catalysts for hydroxylation of substrates ranging from simple alkanes to
25,26pharmaceuticals . In this method, random mutations are introduced into BM3 and the
resulting mutants are screened in high throughput for activity on a desired novel
substrate. Although this activity-based screening methodology can not be used directly to
evolve new specificity for MRI sensing, it suggests that a similar approach might be
possible to create sensors for molecules like dopamine.
A second potential platform for genetically engineered MRI sensors is the iron
storage protein ferritin (Ft). Ft comprises a l2nm protein shell and an 8nm
antiferromagnetic iron oxide core containing up to 4,000 iron atoms27. Ft induces T2
relaxation in MRI and has been studied as an endogenous source of anatomical contrast
28-30
and an exogenous marker of gene expression . Aggregation of Ft after proteolysis31 or
chemical cross-linking3 2 has been shown to enhance its T2 contrast, suggesting that Ft-
based sensors could be made analogously to those previously created using synthetic iron
oxide nanoparticles 5 '33' 4
Ft nanoparticles comprise 24 heavy chain (HF) and light chain (LF) subunits
which self-assemble into symmetrical nanoparticles at ratios proportional to their relative
expression levels3 5 . The N-termini of LF and HF are exposed at the nanoparticle surface,
and can thus serve as sites for genetic fusion of surface functional groups3 6. Analogously
to synthetic SPIO-based sensors, surface functional groups could be fused to Ft subunits
that caused Ft nanoparticles to aggregate in response to the presence or activity of
specific target molecules. A combination of fusion constructs and wild-type subunits
could hypothetically be co-expressed at particular ratios to achieve desired surface
properties and sensor performance, and the entire sensor would then be genetically
encoded, preserving the advantages of design, synthesis and delivery of protein-based
sensors.
1.6 Targets for molecular sensor development: dopamine and protein kinase A
In working towards a proof of concept for molecular sensors for MRI based on
BM3h and Ft, we selected targets that were compatible with the basic operation of each
sensor. This meant selecting a small molecule for BM3h and a molecule whose activity
triggered the binding of two protein moieties in the case of Ft. We also chose targets that
were of high value to neuroscience and for which no non-invasive sensors have
previously been developed. These targets we dopamine for BM3h and protein kinase A
for Ft.
Dopamine (DA) is a neurotransmitter of particular interest because of its role in
learning, reward and motor coordination37. Dysfunction of dopaminergic systems is
implicated in addiction38 and neurodegenerative diseases 9 . Most measurements of DA
release in basic research rely on invasive techniques like microdialysis4 0 and
voltammetry4 1, which report variations of DA concentration at a single site in the brain.
Positron emission tomography (PET) is used to monitor DA receptor occupancy and
related variables42 . PET methods are sensitive, but have relatively low spatial resolution
(> 1 mm); and because most PET measurements are based on kinetic modeling, they are
best suited to studies of chronic conditions or temporal changes that occur on the time
scale of many minutes or longer. To build an understanding of how DA functions in
brain processing, there is therefore a need to develop measurement techniques that could
be applied at a whole-brain level, and that have significantly better spatial and temporal
resolution than PET. MRI, in combination with a suitable contrast agent sensor, would
help satisfy this need.
No MRI contrast agent for sensing DA (or any other neurotransmitter) has been
reported to date, and the specifications for such an agent are strict. DA fluctuations in the
basal ganglia of the brain, for instance, take place on the order of seconds, and involve
peak DA concentrations < 100 gM43' 44. A DA sensor must therefore respond quickly,
reversibly, and specifically to DA fluctuations in the micromolar range. To be
comparable with established functional brain imaging techniques (fMRI), the probe must
45
also be capable of producing image signal changes in tissue on the order of 1% or more4.
Cyclic AMP-dependent protein kinase A (PKA) plays a critical role in memory
formation and is an active target of pharmaceutical development46. PKA forms a key
connection in signaling pathways leading from activation of g-protein coupled receptors
at the cell surface to transcriptional changes in the nucleus. It is activated by cyclic AMP
and phosphorylates a variety of cytoplasmic and intranuclear substrates. A key substrate
of PKA is the transcription factor CREB47 . When the residue Ser133 of the kinase
inducible domain (KID) of CREB is phosphorylated by PKA, CREB binds to the KIX
domain of the activator protein CBP4 8' 49, turning on transcription of CREB-dependent
geneso. Phosphorylation-dependent binding of KID and KIX has been studied
extensively, and fluorescent sensors of PKA activity have been made by fusing these
domains to variants of green fluorescent protein5 ' or p-lactamase5 2 . This suggests that
KID and KIX could serve as Ft-fused surface moieties in a Ft-based MRI sensor design.
No MRI or other non-invasive sensor of PKA activity has been reported.
1.7 Organization of thesis
This thesis is organized in five chapters, beginning with this introduction. Chapter
2 of this thesis, titled "Dynamic imaging with MRI contrast agents: quantitative
considerations" discusses quantitative theoretical considerations underlying the design of
biological sensors for MRI. These considerations are applicable to both synthetic and
protein-based sensors, and helped guide the experimental work described in subsequent
chapters. Chapter 3, titled "Protein-based MRI contrast agents engineered to sense
neurotransmitter dynamics in vivo", describes our work on the BM3h platform for
protein-based sensor development and its use to create an MRI sensor of dopamine.
Chapter 4, titled "Protein nanoparticles engineered to sense protein kinase activity using
MRI", describes our work on ferritin as a platform used to develop a sensor of PKA
activity. Chapter 5 provides conclusions and future directions, and is followed by three
appendixes describing additional results on mammalian expression of BM3h (Appendix
A), studies of the MRI effects of chemically-induced aggregation of Ft (Appendix B) and
full gene and vector sequences for proteins used in this thesis (Appendix C).
FIGURE LEGENDS
Figure 1. Physical principles behind MRI. (a) Left: a single nuclear spin, represented by
it positive charge and magnetic moment (red). Middle: spins are randomly aligned in the
absence of a magnetic field and have zero net magnetization, M. Right: in the presence of
an applied magnetic field, B, spins align with the field and have a net moment M parallel
to B. (b) Left: In an applied field, spins precess about the field axis at a characteristic
Larmor frequency, o. Right: in MRI, an electromagnetic pulse at frequency o is applied
to move spin magnetization perpendicular to the applied field. (c) Left and middle:
representation of bulk spins behaving as described in (b), with 900 spins in middle in
phase with each other and emitting a radiofrequency signal. Right top: in T2 relaxation,
spins stay perpendicular to the field, but lose phase coherence, resulting in a loss of net
magnetization. Right bottom: in TI relaxation, spins regain alignment parallel to the
field.
Figure 2. Prototypical TI and T2 contrast agents. (a) T2 contrast agents are typically iron
oxide nanoparticles of 10-100nm size, with an organic coating, that produce a magnetic
field in their vicinity which dephases aqueous proton spins. (b) TI contrast agents
typically contain paramagnetic metal ions that interact with aqueous protons in a way that
enhances relaxation to longitudinal alignment.
Figure 3. Examples of previously developed MRI sensors. (a) Calcium sensor DOPTA-
Gd from Li at al., in which sensing is accomplished through Ca 2 -dependent changes in
Gd3 accessibility to water molecules. (b) DNA sensor from Perez et al., in which
sensing is accomplished by DNA-mediated aggregation of complementary DNA-
functionalized SPIOs. (c) Calcium sensor from Atanasijevic et al, in which inter-particle
binding is allosterically regulated by Ca.
Figure 4. Magnetic properties of hemoglobin. (a) Illustrated structure of Hb, with four
heme groups containing iron. (b) Illustration of the Hb heme group without (left) and
with (right) oxygen bound. Deoxy heme is paramagnetic and produces T2 contrast.
Oxyheme is diamagnetic.
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2. Dynamic imaging with MRI contrast agents:
quantitative considerations
ABSTRACT
Time-resolved MRI has had enormous impact in cognitive science, and may
become a significant tool in basic biological research with the application of new
molecular imaging agents. In this paper we examine the temporal characteristics of MRI
contrast agents that could be used in dynamic studies. We consider "smart" Ti contrast
agents, T2 agents based on reversible aggregation of superparamagnetic nanoparticles,
and sensors that produce changes in saturation transfer effects (CEST). We discuss
response properties of several agents with reference to available experimental data, and
we develop a new theoretical model that predicts the response rates and relaxivity
changes of aggregation-based sensors. We also perform calculations to define the extent
to which constraints on temporal resolution are imposed by the imaging methods
themselves. Our analysis confirms that some small T1 agents may be compatible with
MRI temporal resolution on the order of 100 ms. Nanoparticle aggregation T2 sensors
are applicable at much lower concentrations, but are likely to respond on a single second
or slower time scale. CEST agents work at high concentrations and temporal resolutions
of 1-10 s, limited by a requirement for long presaturation periods in the MRI pulse
sequence.
keywords: contrast agent, molecular imaging, sensor, temporal resolution,
superparamagnetic nanoparticle
INTRODUCTION
Many of life's most important processes occur within a fraction of a second. With
temporal and spatial resolution orders of magnitude cruder than optical imaging, MRI
seems a deeply insufficient tool for investigation of this "short-timescale physiology."
But with opaque specimens, noninvasive imaging with MRI may still be a uniquely
valuable approach. Echo planar pulse sequences allow images to be collected in tens of
milliseconds-fast enough to freeze-frame the beating heart or record rapid fluctuations
of blood flow in the brain . In many other contexts, the limitation on MRI has not been
its intrinsic acquisition rate, but rather the absence of contrast mechanisms that can
translate biological events of interest into MRI-detectable signal changes.
Newly developed contrast agents, products of the growing field of molecular
imaging, are beginning to change this situation 4 . Several groups have introduced
agents useful for mapping static or slowly varying patterns of gene expression and
epitope distribution 15, 56-5. Contrast agents have also been developed for sensing more
dynamic variables such as pH 59-61, oxygen tension (pO2) 62, 63, ion and metabolite
concentrations 14, 64, 65, and enzyme-catalyzed reactions 1' 5. These agents have been
referred to as "smart" contrast agents, and function as sensors in MRI, analogous to
fluorescent probes used in optical imaging and microscopy. Some MRI sensors could in
principle be applied to study fast (generally cellular) physiological events, for example:
endocytic pH changes during vesicle recycling on the one second time scale, calcium
signaling transients lasting 10-100 Ms, PO2 fluctuations within 2 s of modulations to
oxidative metabolism, and changes in protein phosphorylation in seconds to minutes
during neuronal synaptic plasticity. In each case, however, the practical time resolution
attainable with contrast agent-enhanced MRI may be limited by the agent's molecular
properties and by the physical requirements of contrast generation.
Characteristics of contrast agents and methods for their detection vary widely.
Historically, the most commonly used are small paramagnetic metal chelates which act
by shortening Ti (longitudinal) relaxation times 66. MRI sensors (Figure 1) have been
constructed from these agents by coupling determinants of their T1 relaxivity-solvent
accessibility, rotational correlation time, or the spin and redox state of the metal [?ref?]-
to the presence of specific molecular targets. Sensors based on T2 (transverse) relaxation
rate changes have also been produced, most recently by coupling the aggregation state of
superparamagnetic iron oxide nanoparticles (SPIOs) to physiological signals of interest.
Aggregation of SPIOs even in concentrations as low as 10 mg/L can change observed
T2's quite dramatically 15. A third family of MRI sensors has been based on chemical
exchange saturation transfer effects (CEST) 13. Labile protons or water molecules bound
to a CEST agent can be selectively saturated, and will exchange with bulk solvent
protons to decrease the local MRI signal. In CEST-based sensors, the exchange rate or
chemical shift of bound protons is modulated by interaction with the sensor's target 67,68
To be useful for dynamic imaging studies, an MRI sensor must produce a fast and
large enough signal change to be detected on the desired timescale. Although the steady-
state detection thresholds for various contrast agents have been discussed extensively in
the literature (e.g. 69-72), the interaction between sensitivity and dynamics has been less
thoroughly examined. At the same time, a systematic analysis of advantages and
disadvantages of available contrast mechanisms is essential to the development of
effective strategies for fast-timescale molecular imaging. In this paper, we review the
molecular mechanisms of some paradigmatic smart Ti-, T2-, and CEST-based contrast
agents, and consider the agents' response rates using a combination of simulations and
reference to existing experimental data. Throughout the paper, we estimate the temporal
resolution of each molecular imaging strategy as the inverse of the duration of the
impulse response that relates an underlying stimulus or change in conditions, via the
contrast agent and MRI pulse sequence, to a detectable signal change. Because of the
importance of the MRI acquisition method in determining this temporal resolution, we
include a discussion of detection methods themselves along with consideration of the
different classes of molecular imaging agents.
MATERIALS & METHODS
Bloch equation simulations
Magnetization trajectories were estimated by using Euler integration of the Bloch
equations to simulate one or two spin-pool evolution in the presence of relaxation and
chemical exchange. Radiofrequency (RF) excitation pulses were modeled as
instantaneous rotations, and Larmor precession was omitted from the calculations.
Presaturation used in CEST simulations was modeled as a R pulse train delivered at fixed
frequency (generally 2 kHz) during a presaturation period TP. Parameter settings are
noted where appropriate in the text. Time steps used in the calculations were chosen to
be a factor of ten below the smallest characteristic time relevant to the simulation.
Macroscopic susceptibility effects (i.e. T2* relaxation components) were omitted. All
simulations were performed using custom routines running under Matlab (Mathworks,
Natick, MA) on a Linux-based workstation.
SPIO aggregation simulations
SPIO aggregation and disaggregation were simulated using the Euler method,
applied to the Smoluchowski equation [see Eq. (16) below], which describes the
transition rates among single particles and aggregates of all allowable sizes. The
aggregation kernel Kagg, adapted from Odriozola et al. 73, describes the rate constant for
binding of two aggregates of compositions (i, j) and (k, m) as a function of their
diffusion-limited collision rate and their probability of sticking upon collision:
P ,, (i, j,k, m)e[(i + j)(k+ m)]'
Kagg (i,j, k, m)= k(i,j, k, m) )tick
1 + Ptic(i,j,k,m) f[(i + j)(k + m)] - I(
where Eand b correspond to Odriozola's constants NI1 and b, respectively, with respective
values of 6.1 and 0.35. kdl(i,j, k, m) is the diffusion-limited collision rate due to Brownian
motion, given by:
kd(i,j,k,m)=2 T ( i+j] [k+mI1]t[i+j]4+[k+m]" (2)
where kB is the Boltzmann constant, T is the absolute temperature, fl is the medium
viscosity and df is the fractal dimension of the aggregates (assumed to be constant
throughout aggregation). Pstiek(i, j, k, m) is the sticking probability of the two aggregates,
given by:
P,,ck,(i,j,k,m) = PLNi N" m+ kj+ N' k+ mjN (3)
where Nx for x=ij,k,m represents the fraction of functional groups of the corresponding
type available for binding, e.g.:
N =(f )- i -+1 (4)
fi
where f is the number of functional groups per particle and (i, j) is the aggregate
composition. P11 is the sticking probability for a collision of two oppositely-
functionalized monomers, which we estimated by assuming cubical geometry for the two
types of functional groups, with sides of length da and db and calculating the fraction of
the particle surface that is covered by the functional group (for given functionalization
ratios f and g and particle radius r). The product of these surface fractions is then
multiplied by the bimolecular sticking probability Pbm for free functional groups in
solution, which may be roughly estimated as the ratio of their known binding on-rate ko,
and their theoretical diffusion-limited collision rate. We include an additional factor of 6
to account for an assumption that the cubic functional groups are optimally oriented on
the particle surface. The resulting expression is:
p 6fd2 6gd2' (5)
The fragmentation kernel Kfrag, adapted from Laurenzi and Diamond 74, describes
the rate constant of fragmentation of an aggregate of composition (i + k, j + m) into two
aggregates (ij) and (k, m):
K 1,ag (ij,k,m)= ko,,f [A(i,j)Ag(k,m)+ A,(k,m)Ag (ij)] N1 (ij)N (k, +m) (6)Nj, i+ k, j + m)
Here, kogf is the bimolecular dissociation rate for the complimentary functional groups. A4
and Ag are the number of free functional groups of the two types in aggregates of a given
composition, i.e.:
A,(i,j) = (f -1)i - j+ 1; Ag(ij) = (g -1)j - i+ 1 (7)
Niso is a combinatorial factor describing the number of possible arrangements of particles
in an aggregate of a given composition:
= f'g'(fi -i)!(gi-)! (8)[A,(i,j)) [A,(i,j))i!j!
In order to minimize the computational cost of our simulation, we imposed an upper
limit on the allowed aggregate size, C(z, z), with z = 45. This limit allowed the kernels to
be pre-defined, greatly speeding up the simulations. Under simulation conditions that
favor extensive aggregation, this limit causes an underestimation of average particle size
and an accumulation, or "bunching", of the aggregate population at sizes near the
maximum. However, the parameters used in most of our runs produced aggregates with
average sizes well below this upper limit, and resulting size distributions that did not
exhibit significant bunching. When noticeable bunching did occur, it produced only a
minimal effect on simulation time courses (below 5% for Tobs), with "saturating" effects
on steady-state size evident only when this size approached 2z.
Unless otherwise noted in the main text, the parameters used in our aggregation
simulations were as follows: ko, = 106 M- 1 s-', kof = 6 x 104 s-1 ,f= 50, g = 50, r = 15 nm,
df = 2.2, T = 300 K, T= 1 cp, R2 (non-aggregated relaxivity) = 20 (mM Fe)-1 s- , Fe
atoms per particle = 2064. The same equations and parameters were used to simulate
disaggregation, but with a factor of 102 decrease in ko0 and a factor of 102 increase in koff.
Additional calculations and data presentation. Additional computations, including
calculations of percent signal change for Ti and CEST imaging, were performed using
Matlab. Kaleidagraph (Synergy Software, Reading, PA) and Adobe Illustrator (Adobe
Systems, San Jose, CA) were used in the preparation of figures.
RESULTS & DISCUSSION
Dynamic imaging with smart T1 contrast agents
Temporal resolution of Ti-weighted imaging. Several of the first MRI sensors
were Ti agents synthesized by Meade and colleagues, that respond to their targets with
14,57
roughly two-fold changes in T1 relaxivity 14. Changes in T1 induced by these agents
are usually detected using gradient-recalled echo (GRE), spin echo (SE), or inversion-
recovery (IR) imaging pulse sequences 75. The T1 observed in the presence of a smart T1
contrast agent is given by the approximation, generally valid for low agent concentrations
([M]):
1 1
=--+ Ri(t)[M] (9)
Ti(t) T10
where TiO is the background T1 in the absence of contrast agent and Ri(t) is the time-
dependent relaxivity of the contrast agent; R1(t) could also be rewritten as RI 0 + ARJ(t),
where RI 0 is the "resting" relaxivity and AR1(t) is the temporally varying component of
relaxivity, typically linked to a phenomenon of interest.
The sampling rate of a time varying Ti-weighted signal is determined by 1/TR,
where TR is the repetition time of the pulse sequence; entire three-dimensional volumes
may be acquired with each repetition if echo planar readout (EPI) is used. The contrast-
to-noise ratio (CNR) of a GRE or SE imaging method designed to detect changes in T1 is
maximized when TR equals <T1(t)>, the average value of T1 over time, and when Ernst
angle radiofrequency (RF) excitation is used [in a GRE pulse sequence, this means that
the flip angle a would be set equal to cos-1(exp{-TR/T1})]. In contrast, the temporal
resolution of a Ti-weighting scheme is maximized when the RF flip angle is set to R/2-
only under this condition is the signal observed at each time point independent of the Ti
observed in the previous acquisition. For the same reason, GRE or SE imaging with R/2
excitation achieves better temporal resolution than IR imaging, despite the advantages of
IR for measurements of absolute Ti. Figure 2 demonstrates these effects in simulated
Ti-weighted signals acquired with n/2 and Ernst angle GRE, and with standard IR pulse
sequences. Practical consequences of the sensitivity of dynamic Ti-weighted imaging to
flip angle are that SNR sacrifices may be required to optimize temporal resolution,
particularly for short TR values, and that spatially-varying RF excitation (e.g. produced
by a surface coil) is likely to produce inhomogeneous temporal dependence.
With Ti-weighted GRE or SE acquisition (echo time << T2, TR) and ideal n/2 pulse
excitation, the relative signal (I,) at the end of the nth acquisition period is given by:
I oc 1-exp - tfl+TR I dt (10)
" n-I T1(t)
where t,_1 and t, (= t,_1 + TR) are the RF excitation times preceding the (n-1)th and nth
acquisitions, respectively. The recorded Ti-weighted MRI signal therefore reflects the
history of Ti between each RF excitation and the next, so contributions from
instantaneous events cannot be recognized with temporal resolution better than that
defined by TR. Assuming ideal flip angles are used, the time resolution of a Ti-weighted
molecular imaging experiment will therefore be limited by the smallest TR consistent
acceptable MRI contrast changes given the amount of Ti change produced by the
contrast agent and the noise level of the scanner.
Response rates of Ti-based MRI sensors. Ti contrast agents are typically organic
complexes containing a paramagnetic metal ion such as gadolinium (Gd), which strongly
promote the relaxation of the water protons due to the influence of unpaired electron
spins of the metal ion. Factors that are important in determining the relaxivity of a
contrast agent (reviewed in 66, 76) are contained in the Solomon-Bloembergen-Morgan
(SBM) equations; these include timescales for various molecular motions, structural
features of the contrast agent, and spin properties of the paramagnetic metal ion. Some of
these properties can be manipulated in such a way as to produce a change in relaxivity
coupled to specific events. Among them are the coordination number of the water
molecules, q, the lifetime of the water molecule in the complex, T., and the rotational
correlation time of the whole complex, rR . If one of these parameters differs
significantly between two "states" or conformations of a contrast agent, the intensity of
the signal observed with MRI is also changed. The timescale on which the change occurs
is strongly dependent on the type of the contrast agent and which property has been
affected.
The best explored class of Ti contrast agents relies on the change in solvent
exposure to the paramagnetic metal ion (Figure 1A) 77 . The resting state of the contrast
agent usually has relatively low relaxivity, with limited water access to the metal ion.
The contrast agent is switched into a state of higher relaxivity by a biochemical trigger,
such as the activity of an enzyme or a spike in concentration of an intracellular
messenger. Several agents that work by this type of mechanism have been reported in the
literature. Louie et al. 57 synthesized a caged contrast agent called EgadMe, which is a
substrate for the enzyme #-galactosidase. The activity of j-galactosidase uncages the
agent by cleaving a galactopyranosyl group, exposing a Gd coordination site to raise the
agent's effective q from 0.65 to 1.02; this structural change in turn gives rise to an
increase in Ti relaxivity from 0.903 to 2.72 mM- s1 (measured at 11.7 T). Like many
enzymes, P-galactosidase obeys so-called Michaelis-Menten kinetics, meaning that the
rate of product formation depends on parameters kcat and Kmin the following equation:
V = kcat[E][S]
Km + [S]
where [E]o is the total enzyme concentration, [S] is the substrate (caged contrast agent)
concentration, and V is the rate of uncaged product formation in moles per second. The
cleavage of EgadMe takes place with a kcat of 2.4 x 10- nmol U-1 s-1 and a Km of 0.0182
mM; this means for example that a 100 pM concentration of the agent would require on
the order of several minutes to be cleaved by 100 U/mL (- 1 pM) of P-galactosidase.
Enzymes most likely to be useful for activating contrast agents are those that cleave
carbon-carbon, carbon-nitrogen, or carbon-oxygen bonds; these typically have a kcat
significantly smaller than 1 s-1, and are therefore likely to process their substrates over
time scales much longer than the TR of a typical Ti-weighted imaging sequence. In these
cases, the temporal resolution of the method would be limited by the enzyme activity
level, although with large enough enzyme and substrate concentrations the onset of
enzyme activity might be recognized with TR-limited precision.
Faster relaxivity changes are likely to be produced by ion-sensing MRI contrast
agents. Sensors for calcium and for zinc have been produced 14'64; as with EgadMe, they
respond to their targets with conformational changes that expose a bound gadolinium
atom to water. Ti relaxivity changes from 3.26 to 5.76 mM-i s-1 (11.7 T), and from 4 to 6
mM-1 s1 (7 T), for the calcium and zinc sensors, respectively. No kinetic data is available
for either of these contrast agents, but because their mechanisms are somewhat similar to
small fluorescent ion sensors, the response rates of these sensors may be relevant. In
particular, the calcium sensitive agent synthesized by Li et al. has similar affinity and
calcium-liganding groups to Fura-2 and related BAPTA-based "fast" calcium sensors.
These dyes have measured ko, for calcium on the order of 109 M-1 S-1 78. Assuming an
MRI calcium sensor had an equivalent kon and a Kd of 1 ptM, and if it was used at a
concentration of 100 pM to detect (buffered) calcium concentration fluctuations between
0.1 and 2 pM, its overall response rate would be limited by dissociation, and would likely
be close to a millisecond. This rate is two orders of magnitude below practical TR values.
Time resolution in imaging experiments using MRI ion sensors would therefore be
determined by the repetition rate of the imaging procedure.
Another method shown to enhance the relaxivity of a Ti contrast agent is to
increase its rotational correlation time, TR. For small molecules, TR dominates the total
correlation time (Tc), a parameter that enters into the SBM equations and strongly
influences the magnetic field dependence of Ti relaxivity. Since
TrR=-4 a 3rq/3kBT (12)
where kB is the Boltzman constant, changes in TR could be effected either by
manipulating the viscosity (1) or temperature (1) of the system, or by changing the
effective radius (a) of the contrast agent. MRI contrast changes due to changes in the IR
of a Ti agent are sometimes dramatic, and sensors involving changes in TR (Figure 1 B)
may be particularly valuable for dynamic imaging at today's most common clinical
scanner field strengths ( ;3 T).
Sherry and colleagues followed these principles and designed a paramagnetic
peptide (Gd3*-G80BP) that senses its protein target (Gal80) by binding to it 79; a related,
but enzyme-dependent approach was taken in a study by Aime et al. 62 In the
Gal8O/Gd 3-G80BP case, association produces a roughly 25-fold increase in TR,
corresponding to the ratio of Gal80-complexed to free peptide molecular sizes (here
assuming equal density). At 0.5 T, the binding reaction produced a T1 relaxivity change
from 8.3 mM- s-1 to 44.8 mM-1 s . Protein-protein association rates tend to be on the
order of 106 M S-1 80' , meaning that a high-affinity binding reaction initiated by 10 pM
concentrations of dissociated species might approach its equilibrium with a characteristic
time on the order of 0.1-1 s. Dissociation rates for this type of interaction vary widely,
but will be slower for complexes with Kd << 10-5. Because these time scales are on the
order of typical Ti-weighted MRI TR values, sensors based on protein binding-induced
changes in TR may often, but not always, respond with rates that are limiting for the
temporal resolution of a dynamic MRI experiment.
Dynamic imaging with SPIO aggregation-based T2 agents
Temporal resolution of T2-weighted imaging. An endogenous T2 contrast agent
(deoxyhemoglobin) and an exogenous blood-pool contrast agent (mononuclear SPIO, or
MION) have been heavily used in dynamic functional brain imaging experiments (fMRI),
where contrast and temporal resolution are governed by hemodynamic effects 82,
Smart iron oxide agents have also been introduced and applied in cell labeling, cell
tracking, and molecular sensing 15,84. Although they are physically large (10-100 nm), an
advantage of SPIO agents is that they have high relaxivities (10-100 mM-1 Fe s-1), and are
detectable at very low particle concentrations-several orders of magnitude below
concentrations required for most Ti agents 85, 86 SPIO agents also produce magnetic
susceptibility variations that may be visualized even at fairly low spatial resolution by
T2 *-weighted imaging.
T2-weighted imaging is usually performed using SE pulse sequences, sometimes in
conjunction with Carr-Purcell-Meiboom-Gill (CPMG) readout 75. GRE sequences can be
used to produce related T2 *-weighted images. Contrast is established during the echo
time (TE) of these sequences, or across multiple echo times with CPMG. Assuming Ti
and TR are static or that TR >> Ti, the relative T2-weighted signal in a single-echo
(GRE) sequence is given by:
Inoc exp - t ,+TE dt (13)
- nt T2(t)
where T2 is affected by the T2 contrast agent's relaxivity (R2) according to:
1 1 S=- +[R2 0 +AR2(t)][M] (14)
T2(t) T20
where T20 is the background T2, R20 and AR2(t) are the static and time-dependent
components of T2 relaxivity, respectively. Because echo times are usually short (10-100
ms), and necessarily less than TR, the temporal "precision" of T2-weighted imaging can
be considered to be higher than that of Ti-weighted imaging. On the other hand, unless
CPMG or phase-locking strategies are used, the image sampling rate is still limited by
TR, and very short T2 changes may be missed entirely with probability (1 - TE/TR), even
if they would be likely to produce a signal change when sampled optimally. A clear
advantage of scan series data obtained with T2-weighted imaging sequences, however, is
that their time dependence does not depend on the RF flip angle.
SPIO aggregation sensors. Several types of T2 relaxation-promoting smart
contrast agents have been produced. Of these, agents based on the aggregation of
biocompatible SPIO nanoparticles demonstrate the largest relaxivity changes, and appear
to be easily tailored to a variety of applications 15. Superparamagnetic sensors are formed
by functionalizing the surfaces of SPIOs with molecules (usually biomolecules, i.e.
proteins or nucleic acids) that associate with complementary groups on other SPIOs,
either when activated in some way, or when bridged by a particular target molecule of
interest. Because the particles are multivalent, this binding or bridging induces formation
of aggregates, somewhat similar to the process of immunoprecipitation. Aggregation can
dramatically amplify the transverse relaxivity of SPIOs, significantly reducing the T2
relaxivity even of very dilute SPIO suspensions (< 10 mg/L Fe). Ralph Weissleder and
colleagues pioneered this approach and have applied it to make MRI sensors for specific
oligonucleotides, protease and nuclease activity, and protein-protein binding, including
antibody/epitope recognition 15' 87 Our group has adapted the approach to construct an
88SPIO bioconjugate sensor for calcium
The strong T2 effects produced by SPIO sensors make these contrast agents
potentially attractive tools for dynamic MRI studies in vivo. Little is currently known,
however, about the response dynamics of aggregation-based sensors. Most of the
existing SPIO sensors appear to respond to their targets on a several-minute time scale,
though some enzyme-dependent variants are slower. It is currently unknown to what
extent design characteristics of the sensors affect rates of aggregation and concomitant
relaxivity changes. Given the relative absence of experimental data related to
biofunctionalized nanoparticle aggregation kinetics, we here explore theoretical
determinants of SPIO aggregation dynamics in some detail through computational
modeling, with the goal of identifying key parameters affecting the time courses and
extents of aggregate formation. In addition, we apply a rudimentary approach to
approximating changes in T2 relaxivity produced by SPIO aggregates; this allows us to
convert calculated aggregation times into estimated MRI signal changes.
Model of SPIO aggregation behavior. To model physiologically-induced SPIO
aggregation dynamics, we considered the following reaction scheme:
activation aggreg. l1, C(ij)Ai* Bj*A + B A* + B* (15)X, C(i, j)
where A and B denote two types of bioconjugated SPIO nanoparticles with different
functional groups. Under resting or baseline conditions, the groups on A and B particles
have minimal binding affinity for one another. When one or both of the two types of
functional groups are activated (converting A to A* and B to B*), their binding affinity
increases, initiating the process of particle aggregation. The end-product of the
aggregation is a distribution of clusters [denoted by the summation ratio on the right hand
side of Eq. (15)] with compositions Ai*By* and concentrations C(i, j), where i is the
number of A-type particles andj is the number of B-type particles in a given aggregate of
total size i + j. Disaggregation can be induced by deactivating the functional groups,
causing dissociation at the molecular level; here we assume that dissociation need not
precede deactivation. For simplicity, we also assume that the activation and deactivation
steps happen much faster than aggregation and disaggregation. In many cases, this is a
reasonable approximation, given the relatively slow timescales for aggregate
(dis)assembly (1-1000 seconds) compared to the time scales of potential (de)activation
events (e.g. milliseconds for Ca 2 -induced protein conformational changes). Some
triggering events, like enzymatic proteolysis, might be much slower however, in which
case the fast-activation condition would be violated and the model we develop would
have to be modified.
Aggregation phenomena are commonly formulated using the Smoluchowski
equation 89, a general differential equation describing the formation and fragmentation of
various size aggregates. The Smoluchowski model assumes that every transition in the
system involves either the break-up of an aggregate into two smaller species, or the
agglomeration of two aggregates into a larger cluster:
dC(u,v) 1 Vdt - -1  Kagg (ij, u - i,v - j)C(i,j)C(u - i,v - )
dt i= j=0
- Kfiag (i, j, u - i, v - j)CQu, v)
2i=0 j=0 (6010- (16)
-1 IKagg (ij, u,v)C(i,j)C(u,v)
i-0 j= 0
+Z Kafrg(i,j,U,V)C(U+ i,v + j)
i=0 j=0
Here, C(u, v) is the concentration of aggregates that contain u particles of type A and v
particles of type B. The coefficients Kagg and Kag are "kernels" for aggregation and
fragmentation-they function like rate constants, and reflect the probability that
aggregates of size (u, v) will be formed by or broken into clusters of all other allowed
sizes. The first term of equation (16) is the instantaneous rate at which aggregates of
composition (u, v) are formed through the binding of all possible pairs of smaller
aggregates. Similarly, the second term accounts for the breakup of (u, v) clusters into all
possible smaller fragment pairs. The third term is the rate at which aggregates of
composition (u,v) bind to other clusters. The final term is the rate at which (u, v) clusters
break off from larger aggregates of size (u + i, v + j). Kagg and Kag were adapted from
the literature 73' 74 in order to reflect the scenario in Eq. (15). As is common in other
models, our approach assumed that the aggregates are fractal (irregular at all length
scales) and non-circular (any two particles are connected through only one chain). These
assumptions are valid for rigid particles with small (protein-sized) functional groups
tightly anchored to the particle surface. See the Methods for further details.
In order to simulate the aggregation of SPIOs, we used Euler integration to obtain
mass-action solutions to Eq. (16). Figure 3A shows representative aggregation and
disaggregation time courses produced by our simulations. We depict both the mass-
averaged mean particle radius <r> (relative to an individual particle), and the mass-
averaged mean aggregate size <n> as functions of time. The corresponding steady-state
distribution (limit at infinite time) of aggregate sizes and compositions is shown in Figure
3B. These time courses and distributions are consistent with results from previous Monte
Carlo simulations and experiments involving general reversible aggregation phenomena
74, 9. To facilitate the comparison of time courses for varying sets of parameters, we
defined an "apparent" aggregation time constant Tos as the value for which [<n>(Tbs) -
<n>(O)] equals (1-1/e)[<n>(oo) - <n>(O)], where <n>(oo) is the steady state value of <n>
(as t goes to infinity), for an aggregation process initiated at t = 0.
Our simulations investigated the dependence of Toss and <n>(oo), on the total
nanoparticle concentration, the number of functional groups per particle and the
concentration ratio of complementary particles. The results, shown in Figure 3C,
demonstrate a generally non-linear dependence of Toss and <n>(oo) on these parameters.
As concentration increases, both the rate of approach to equilibrium and the steady state
size rise in a supralinear fashion (panel Ci), as would be expected for a multi-body
process. For increasing number of functional groups per particle, Tobs approximates an
inverse exponential dependence, while <n>(oo) increases roughly linearly (panel Cii). As
shown in panel Ciii, the maximal aggregation rate and size are found when the
concentrations of complementary particles are equal. Overall, these results suggest that
the kinetics of aggregation are highly sensitive to the particulars of their design and
deployment, with aggregation times varying over three orders of magnitude within a
feasible concentration and functionalization range. At the higher end of this range,
theoretically achievable aggregation times are as short as several seconds.
As shown in the sample time courses of Figure 3A (gray regions), disaggregation
upon the removal of the activating physiological stimulus can occur on time scales
considerably faster than those seen for aggregation. However, the rate of disaggregation
can vary widely depending on the specific deactivation mechanism. For example, given
an allosteric mechanism where activation and deactivation of particle functional group(s)
can occur in both bound and unbound states, deactivation can be expected to increase
dramatically the bimolecular dissociation rate koff (in addition to reducing kon), leading to
fast disaggregation. By contrast, if the functional group(s) can only be deactivated in the
unbound state, koff remains unchanged for bound particles, resulting in a much slower
disaggregation process. In general, at low nanoparticle concentrations, we expect
disaggregation to occur faster than aggregation, making aggregation the limiting factor in
the reversible response rate of an aggregation-based sensor.
It should also be noted that the rates of aggregation and disaggregation in biological
tissues (e.g. cell cytoplasms) may be significantly slower than the rate observed in
solution 91. Experiments have shown that molecular crowding in the cellular milieu
reduces the effective diffusivity of solutes in a size-dependent manner, decreasing it by
roughly a factor of four for most biological molecules, and by a factor of 40 or more for
particles with diameters above a 50-80 nm threshold. Single SPIOs in the 30 nm size
range should fall below this threshold, but aggregates larger than a certain size will be
above it. Since under many conditions monomers are the single most common species in
the aggregation reaction, it may be possible to roughly approximate the slowing of
aggregation in the cellular environment by dividing the Brownian diffusivity constant by
around a factor of four (here we assumed that diffusion of each aggregate was determined
by the Stokes-Einstein equation only).
SPIO aggregation-induced changes in relaxivity. The model developed above
makes predictions about the dependence of SPIO aggregation rate on various parameters
of MRI sensors; aggregation time constants are likely to vary from several seconds to
many minutes, depending on concentration, functionalization, monomer ratio, and, in
biological environments, size. But how is the aggregation rate of these particles likely to
translate into MRI-observable signal changes? Although strong changes in T2 relaxivity
upon aggregation of SPIOs have been reported, little work has been done to explain the
mechanism of aggregation-induced contrast change. Previous theoretical analyses,
Monte Carlo simulations, and experimental work have shown that the T2 relaxivity of
iron oxide nanoparticles is well-described by the motional averaging approximation when
mean Larmor frequency shift at the particle surface (AO) and the time constant for water
diffusion around the particle (td) satisfy the condition TdAo < 1 31, 92. This condition is
fulfilled for uncoated iron oxide crystals smaller than approximately 30 nm. For coated
SPIOs such as MION-46 93, which contains a crystalline core of around 5 nm diameter
surrounded by an organic shell of roughly 10 nm thickness, this maximum size for
motional averaging is relaxed to around 350 nm, due to a lower field strength at the
particles' water-accessible outer surfaces.
In the motional averaging regime, outer sphere theory predicts the component of T2
relaxation due to a suspension of field-perturbing SPIO particles to be given by:
1/T2spjo =(4 /9)V(ACO) 2 ,rd (17)
where V is the volume fraction of solution occupied by the particles, Td is defined as
Trd = r 2 ID, where r is the particle radius and D is the self-diffusion coefficient of water,
and Ao is given by Aw = (I/3)puOM, where M is the particle magnetization, pA is the free
space magnetic permeability, and y is the proton gyromagnetic ratio.
For aggregate sizes below the motional averaging cutoff, Eq. (17) and the definition
of td predict an increase in relaxivity proportional to the square of aggregate radius. For
fractal aggregates, the relationship between the number of particles in the aggregate (n)
and its radius of gyration (r) is:
r oc n" (18)
where df is the aggregate's fractal dimension. Typically, df is between 1.75 and 2.3 in
fractal aggregates 94' 95, with reaction-limited aggregation (see above) resulting in larger
df
In addition, Eq. (17) and the definition of Ao predict a quadratic dependence of
relaxivity on particle magnetization, M. At field strengths above 1 T, SPIO magnetic
moments are known to be saturated 93. Under these conditions, M is field-independent
and roughly proportional to p, the density (number of particles within the volume defined
by r) of a given aggregate:
3
M OCpO C C rf- 3 c n (19)
r3
Because V and D are independent of aggregation state, we can combine Eqs. (17-19) to
obtain a set of proportionalities:
2-4
1/T2SPIO " p2 r 2 df- 4 df (20)
Since at (typical) low SPIO volume fractions 1/T2SPIO is approximately equal to R2 times
the particle concentration [cf Eq. (14)], Eq. (20) predicts an increase in T2 relaxivity with
increasing aggregate size when the fractal dimension is greater than 2. In the limiting
case where aggregates are composed of fully-packed spherical particles (df = 3) the
proportionality reduces to an r2 dependence.
We simulated fractal aggregates with df = 2.2, which is on the high end of the
reaction-limited aggregation regime. This choice of df is somewhat arbitrary, and one
would expect the fractal dimension to vary considerably depending on the details of
particle geometry and functionalization. Although variation of df within the typical range
would have a large effect on predicted relaxivity, our simulations demonstrated that it had
a negligible effect on kinetics (data not shown). For aggregates with df= 2.2, relation
(20) predicts a relaxivity proportional to n2. In order to characterize the relaxivity of a
given population of aggregates, we therefore calculated the mass average of n2/11 and
scaled it by the known single-particle relaxivity.
Figure 4A shows the temporal evolution of relative relaxivity (normalized by the
unaggregated particle relaxivity) and corresponding percent change in MRI signal
intensity during the SPIO aggregation and disaggregation time courses shown in Figure
3A. Signal intensity was calculated by assuming a baseline T2 for the medium of 100 ms
and setting the TE to the T2 observed in the presence of non-aggregated SPIOs. Figure
4B shows the predicted apparent time constant (Tobs, defined as above) of the change in
MRI signal intensity, along with the maximal steady-state signal change, as a function of
particle concentration. These results suggest that single-second temporal resolution may
be possible for aggregation sensors with particle concentrations in the 20-100 nM range,
but that lower SPIO concentrations will lead to considerably slower response rates. From
a practical standpoint, it is also useful to know how long it takes the aggregation-induced
signal change to reach a minimal detection threshold. We defined T5% to be the time it
takes to obtain a 5% change in signal, during aggregation of initially fully disaggregated
particles. Figure 4B shows that at high concentrations, T5% is predicted to be of order 0.1
s, but that at lower concentrations, where 5% is close to the maximal signal change, T5%
is close to 100 s, and actually longer than Tobs.
Time-resolved imaging with CEST agents
Temporal resolution of CEST-based imaging. The chemical exchange saturation
transfer (CEST) effect 13 has recently been explored as a basis for MRI contrast agents
because of its potential independence of paramagnetic metal complexes and possible
advantages in sensitivity compared with some Ti contrast agents. CEST contrast
enhancement is achieved by selectively saturating the proton magnetization of a small
pool of labile protons associated with a CEST agent; these protons exchange with bulk
solvent, producing a decrease in the bulk magnetization that gives rise to the detected
MRI signal. CEST techniques have been applied to produce contrast changes in vitro,
using a variety of agents including paramagnetic lanthanide complexes (PARACEST
agents) 96. CEST contrast changes have also been created in vivo using saturation of
amide protons of endogenous proteins or exogenous species 17, 18. With CEST-based
sensors, the efficiency of saturation transfer from the agent depends on select features of
the agent's chemical environment, giving rise to modulations in detected MRI intensity
that could in principle be followed in a dynamic imaging experiment.
In CEST MRI, saturation transfer to longitudinal bulk magnetization takes place
during a presaturation period TP, after which RF excitation is delivered and any CEST-
related changes in bulk magnetization are measured with a standard readout module
(GRE, SE, EPI, etc.). Usually TP is set to be almost as long as TR, in order to maximize
CEST contrast for the given repetition rate. Observed CEST-dependent magnetization is
influenced by the inherent spin-lattice relaxation rate of bulk water protons (1/T1]), by
the time constant (tm) for chemical exchange between CEST and bulk proton pools
during the presaturation time, and by the efficiency and dynamics of the saturation itself.
With a smart CEST contrast agent, tm and the saturation efficiency could depend on the
configuration of the agent and would become time-dependent variables.
Analytical expressions for CEST-dependent MRI signal changes can be obtained
under various simplifying assumptions 68, 71 A reasonable assumption is that the
magnetization of the CEST pool reaches a steady state very rapidly during saturation (i.e.
much faster than TP). A further approximation is that RF irradiation of the CEST pool
does not directly saturate the bulk proton pool-this is true when the RF offset (Ao)
between the bulk water frequency (0i) and CEST pool frequency satisfies: Aoyo >> 1.
If these two conditions are met, and the steady-state partially-saturated magnetization of
the CEST proton pool is given by (1 - a)Mos (with M being the equilibrium
magnetization of the saturated CEST pool and ax the fractional saturation of this pool), the
following differential equation describes the evolution of bulk proton magnetization
during TP:
dMzwt (Mow - M,,) aM"dA~(t ~4 ~--4~ aL (21)
dt Tj, T,
L E L E [ Tw 111 Tm/c, where c is the concentration of exchange sites on the CEST
agent, and given a bulk proton concentration of 111 M. Assuming perfect RF flip angles
(see Ti discussion above) and ideal CEST-weighting (TE << T2 < TR ~ TP), a formula
for relative signal observed in a serial imaging experiment can be obtained by integrating
Eq. (21) over TP, with the initial condition that bulk magnetization is transverse (Mzw
0) before saturation begins:
Ioc T - exp f- + a TP (22)
jr + aT, rw + aT] I rTh,
If a CEST-based MRI sensor was being used, terms in Eq. (22) would be replaced with
integrals over TP, similar to Eqs. (10) and (13) (omitted here for notational simplicity).
Because CEST contrast develops during the entire saturation period, the temporal
resolution of a CEST experiment cannot exceed l/TP. In analogy to the role of TR in T1-
weighted molecular imaging, the requirement that TP be long enough to obtain sufficient
CNR therefore sets a practical limit on the repetition time for MRI time series using
CEST-based sensors.
Figure 5 shows a contour plot of ideal CEST signal changes as a function of TP and
t m, assuming a CEST agent is "turned on and off' with each image acquisition. The plot
was calculated using Eq. (22), and overestimates signal change for cases where the RF
offset (Auo) between the bulk water frequency (wi) and the saturated pool fails to satisfy
Aao >> 1, when Ao and the proton exchange time fail to obey mAo >> 1, or when X <
1 (as often expected under practical saturation powers). For any given noise level, the
signal changes reported in the figure suggest realistic limitations on scan rate. The well-
known dependence of the CEST effect on Tm translates into faster possible time
resolution for agents where saturation transfer changes occur around smaller Tm values.
The plot extends to Tm's less than 10 pts, which have been reported for exchanging sites
on some lanthanide complexes; at field strengths below 10 T, however, application of
these complexes is likely to be compromised by the requirements on mAuo. As with T1-
weighted imaging, the use of nonideal flip angles could degrade the temporal resolution
below the CNR-dependent limit, by compromising the independence of each MRI
acquisition. Temporal resolution could also be degraded if the CEST pool magnetization
were not maintained near its steady-state value at all times, but we found no evidence of
this in magnetization evolution simulations covering a broad range of conditions.
Response rates of CEST-based sensors. CEST agents have been used as MRI
sensors for pH, lactate, and glucose 18, 60, 61, 5, 67. In all cases, the response rates of the
sensors are likely to be extremely fast compared with the demands of the imaging method
itself. CEST-based pH sensing is simplest to appreciate, given the well-known
dependence of proton exchange rates on pH. Amide protons of endogenous proteins, and
of two synthetic lanthanide complexes, have been used for pH-sensitive CEST 17, 18, 60
Amide Tm ranges from roughly 10-3 s-I at pH 3 to 103 s1 above pH 9 97, creating a
change in saturation transfer efficiency. The response rates to pH are likely to be
extremely fast, though they have not been measured directly on the contrast agents. Rate
constants for proton association reactions in general are thought to be on the order of 1010
to 10" M-1 sec- 98. Base-catalyzed exchange is most common in the physiological pH
range (pH 5-8) 17; under base catalysis, the association and dissociation rate constants for
glycine amide proton exchange (similar to the CEST pH sensor DOTAM-Gly) are
roughly 1.4 x 1011 and 8.44 x 105, respectively 98. Given these rates, it is likely that the
response of CEST agents to pH changes takes place within a few microseconds. This
time scale is negligible compared with the duration of presaturation pulses used to
measure pH changes from agent concentrations even over 10 mM.
A related mechanism underlies low affinity glucose detection by a complex
synthesized by Zhang et al. 67. The unliganded form of the sensor functions efficiently as
a CEST agent, due to exchange of water molecules at a free europium coordination site.
In the presence of glucose (Kd = 2.6 mM), the exchange site is partially blocked (cf
Figure 1A), leading to a noticeable reduction in CEST efficiency when saturation is
delivered at a -30 ppm RF offset. A somewhat different mechanism allows CEST-based
lactate sensing by an agent called MBDO3AM 65. In its free state, this lanthanide adduct
contains six amide protons, all of which overlap to give rise to a high field-shifted proton
resonance peak at -28.5 ppm. When lactate is added at relatively high concentrations
(the dissociation constant is over 100 pM), the degenerate resonance is resolved into
discrete peaks in a lower field frequency range, -14 to -20 ppm. If saturation is
selectively directed either at the free MBDO3AM amide peaks, or at the complexed-form
amides, a change in CEST saturation efficiency results from binding of the lactate to the
contrast agent. With neither the glucose nor the lactate sensor are kinetic parameters
describing the metabolite/sensor binding interaction known, but by analogy with other
bimolecular binding pairs, the association rates are likely to be well over 105 M-1 S-1,
implying that the dissociation rates are at least 10 s-1. Even given these conservative
estimates, the kinetics of intermolecular interactions that underlie CEST-based lactate
and glucose sensing are still significantly faster than the time scale used to build up
CEST contrast, which was on the order of several seconds in these studies.
Comparison of dynamic molecular MRI methods
Figure 6 presents a comparison of temporal resolutions for dynamic imaging
approaches using smart T1 contrast agents, SPIO aggregation-based T2 sensors, and
CEST agents. For each of the three groups of molecular imaging agents we considered, a
colored area denotes approximate conditions under which acceptable signal changes may
be achieved, assuming realistic MR acquisition conditions. This representation is a
guideline only; it is by necessity highly reductionist, because the full range of relaxivities
and interconnected trade-offs between CNR, repetition rate, spatial resolution, partial
volume effects, and signal averaging are impossible to address simultaneously in
graphical form. Roughly speaking, we assume that a 5% signal change is sufficient for
detection of an agent's response in a time-resolved experiment. This requirement is
lower than the standard generally required in contrast agent-enhanced anatomical (static)
imaging, but reflects the important possibility, specific to dynamic imaging, of
performing statistically-rigorous within-subject comparisons to recognize small image
intensity fluctuations. In human fMRI, the dominant form of time-resolved MRI today,
signal changes lower than 1% are often robustly detected at the single voxel level.
The "fast" Ti agent area in Figure 6 (saturated red) was estimated assuming GRE
imaging with it/2 excitation pulses, and a sensor with relaxivity changes on the
millisecond or faster time scale, from 5 to 10 mM-1 s-1. The region is bounded at the right
by concentration levels at which toxicity and T2 effects may interfere with applications;
at low concentrations, signal changes are likely to be below the detection limit. In
principle TR's close to 10 ms could be used to obtain even higher temporal resolution
than shown, but this would result in severe attenuation of the overall signal, and under
typical imaging conditions would be impractical. Very short TR's would also be
incompatible with EPI volume acquisition. The "slow" TI area in light red refers to T1
agents like the Gal80-binding agent and the -galactosidase substrate discussed above,
for which the molecular rate of response is the limiting factor on potential temporal
resolution. The relaxivity changes produced by these sensors are on the same order of
magnitude as the "fast" agents, but signal averaging becomes a possibility when time
resolution is no longer limiting, so it is likely that somewhat lower concentrations could
be used.
The aggregation-based SPIO agents are represented by the green shaded area. For
these agents, the temporal resolution in T2-weighted imaging is also limited by the
sensors' rates of response, rather than by the imaging itself. The region plotted in Figure
6 is estimated based on the theoretical analysis we have performed here; our modeling
was consistent with data from the literature, but covered a wider variety of conditions
than has yet been experimentally explored. The response times of aggregation-based
sensors are predicted to vary approximately linearly from about 100 s at 1 nM SPIO
concentration to 1 s at 0.1 gM, for particles with ~50 attached proteins; if the
functionalization level is lowered, the rates would be decreased. At SPIO concentrations
into the micromolar range, the aggregation effect would be yet faster, but concentrations
significantly above 0.1 pM (10 mg/L Fe, assuming 2000 iron atoms per particle) would
begin to attenuate the MRI signal too severely, and would be inconsistent with physical
echo times.
The blue area in Figure 6 denotes conditions under which dynamic MRI with smart
CEST agents could be performed. As our earlier discussion emphasized, the temporal
resolutions and concentrations compatible with use of existing CEST-based sensors are
completely constrained by the physical requirements of performing imaging with
acceptable signal changes. To estimate the region in Figure 6, we performed pulse
sequence and magnetization simulations for a 300 ps Tm CEST agent, under a range of
repetition rates and concentrations, with TP ~ TR. Signal changes between exchanging
("on") and nonexchanging ("off') conditions were greater than 5% for concentrations
above 1 mM and for 1-10 s saturation times. If agents with lower t m were used at very
high field, it is likely that lower saturation times or concentrations could be used.
A conclusion from this comparison is that the fastest MRI molecular imaging
temporal resolution (100 ms) is likely to be obtained with Ti agents, while the lowest
concentrations (and greatest signal changes) may be reached with SPIO aggregation
sensors. Several caveats apply: First, most of our arguments have relied on simulations
or calculations performed under idealizing assumptions; some of the findings (especially
the aggregation simulations) await empirical validation and may incompletely account for
realistic experimental conditions. Second, the discussion has focused on time
dependence largely to the exclusion of other factors related to the contrast agents. In an
actual dynamic MRI experiment, some agents with inferior "theoretical" time resolution
may in fact be preferable for unrelated reasons. Third and last, we have not attempted a
comprehensive discussion of all existing or putative smart contrast agents and
mechanisms-the specific agents we have addressed were chosen because they are
representative or of particular interest.
The guide we present in Figure 6, and the more detailed analyses of the previous
sections, give an overview of considerations important to dynamic molecular imaging
experiments. Although few such experiments have been reported to date, time-resolved
molecular imaging of biologically significant targets (particularly in neuroscience and
developmental biology) is clearly an urgent direction in MRI methods development.
Quantitative description of contrast agent properties will help direct both the selection of
viable experimental strategies, and the design of new smart contrast agents with
improved characteristics. Our discussion suggests that high CNR is the most important
requirement for optimizing temporal resolution with Ti agents, where the sensitivity of
the MRI methods currently limits acquisition rates. The development of T2 SPIO agents
with enhanced kinetic properties is also clearly recommended, given the low
concentrations at which these agents can be used; improved SPIO-based sensors could be
produced by maximizing nanoparticle functionalization levels, or by loosely tethering
particles to one another in order to speed aggregation.
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FIGURE LEGENDS
Figure 1. Smart contrast agent mechanisms. Contrast agents have been constructed to
respond to physiological targets by a variety of mechanisms. In (A), binding of a target
molecule (red) to a paramagnetic chelate (green and gray) increases exposure of the
agent's coordinated metal ion (green, usually Gd) to surrounding tissue water (blue),
allowing water molecules to participate in inner sphere interactions with the metal, and
increasing the agent's Ti relaxivity. Enzyme and ion-sensitive contrast agents that work
this way have been synthesized. (B) Association of a lanthanide chelate (green and gray)
with a much larger binding partner (red) results in an increase in rotational correlation
time (TR) and Ti relaxivity. (C) The presence of a target molecule (red) induces
aggregation of functionalized superparamagnetic nanoparticles (green). Aggregation can
induce dramatic changes in T2.
Figure 2. Effect of excitation flip angle on Ti image series. Magnetization trajectories
during Ti-weighted MRI time series were simulated using the Bloch equations. To
model the effect of a smart T1 agent, the Ti of the system was set to a baseline of 1.0 s,
but reduced by a factor of two during a 10 s "stimulus" period (gray boxes). The top two
panels show results from a mock gradient echo (GRE) imaging sequence with 0.5 s TR,
10 ms TE, and 100 ms T2, beginning with longitudinal magnetization at equilibrium (=
1.0). The top panel shows the echo peak signal series obtained when perfect nT/2 pulses
are used for excitation: a transition in signal level takes place sharply after the change in
T1. The middle panel shows the effect of Ernst angle excitation. Although the overall
signal level is higher, the increase in signal after Ti decreases is slower. In the bottom
panel, an inversion-recovery sequence is simulated with a 0.5 s recovery time and 1.0 s
TR. As with Ernst angle GRE imaging, the signal at each acquisition is dependent on the
previous acquisition, and the new equilibrium signal is reached only two or more
acquisitions after a change in T1.
Figure 3. Predicted characteristics of nanoparticle aggregation and disaggregation.
(A) The temporal evolution of mass-weighted average aggregate size <n>(t) (top) and
radius of gyration relative to monomer (bottom) during aggregation and disaggregation.
(B) The steady state aggregate size distribution corresponding to t = 250 s in (A). The
insert shows the composition distribution of the aggregates, with the number of type A
and type B particles on the horizontal and vertical axes, respectively. (C) Apparent
aggregation time constant Toss (circles) and steady-state mass-weighted average aggregate
size <n>( 00) (squares) for a range of initial monomer concentrations (i),
functionalization densities (functional groups per particle) (ii), and concentration ratios
between the complementary particle types (iii). Simulation parameters are listed in the
Methods section.
Figure 4. Relaxivity changes during SPIO aggregation and disaggregation. (A) The
temporal evolution of percent MRI signal change (top) and ratio of net T2 relaxivity,
relative to unaggregated monomer solution (bottom), corresponding to the aggregation
time course shown in Figure 3A. (B) Apparent signal change time constant Tbss (filled
circles), time to reach a 5% signal change T5% (filled squares), and the steady-state
percent signal decrease (hollow diamonds), as a function of initial monomer
concentration.
Figure 5. Computed signal changes in dynamic MRI with CEST agents. Signal
changes were calculated using Eq. (22) in the text, by considering the difference between
signal in the absence and presence of chemical exchange, assuming complete saturation
of the CEST pool (a = 1) over a variable saturation period TP. Black contours show 5,
10, and 25% signal change levels estimated for 100 pM CEST agent. Signal change
contours for 1 mM agent are approximately parallel to these (contour for 5% change
shown in gray), with < 5% signal change observed at all TP values for low Tm. A T1, of
1.0 s was assumed.
Figure 6. Schematic comparison of temporal resolutions for three classes of
molecular imaging agent. Colored regions approximate combinations of temporal
resolution and contrast agent concentration that would lead to acceptable signal changes
(> 5%) with Ti-weighted (red), T2-weighted (green), and CEST (blue) imaging. Ti
agents are subdivided into "fast" agents (saturated red), for which imaging requirements
limit the attainable temporal resolution, and "slow" agents (light red), for which
properties of the agents themselves are limiting. See text for further discussion.
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3. Protein-based MRI contrast agents engineered
to sense neurotransmitter dynamics in vivo
ABSTRACT
Progress in biology and medicine could be accelerated using methods for non-invasive
molecular imaging of living tissues, but the development and application of imaging
agents that could serve this purpose remains a major challenge. Here we applied powerful
protein engineering techniques to create a new type of magnetic resonance imaging
(MRI) contrast agent sensitive to a critical signaling molecule in the brain, the
neurotransmitter dopamine. Multiple rounds of directed evolution were used to identify
dopamine-binding variants of the heme domain of the bacterial cytochrome P450-BM3
(BM3h). Engineered BM3h mutants brightened MRI signal in the absence but not the
presence of dopamine; little or no interference was observed from other neural signaling
molecules. Quantitative measurements of biological dopamine release were obtained and
validated in vitro using cultured PC12 cells. Intracranial injection of BM3h-based
sensors into anesthetized rats produced dopamine-dependent MRI contrast changes and
revealed real-time dynamics of neurotransmitter transport with submillimeter spatial
resolution. Our approach can be generalized to monitor a wide variety of physiological
processes in living organisms.
INTRODUCTION
Discoveries in neuroscience often follow the development of new ways to peer into
the active brain. Magnetic resonance imaging (MRI) has become a particularly valuable
tool for studying the brain because MRI scans are noninvasive and can provide
information at relatively high spatial resolution (< 100 pm) and temporal resolution (~1
s) from living specimens7. Powerful MRI-based techniques for studying neuroanatomy
and brain function have been established, but the range of neuronal phenomena
accessible to measurement by MRI remains limited by the small variety of endogenous
signals. One approach to this problem is to develop MRI sensors that respond
dynamically to aspects of structure or function in neural tissue; these sensors might act in
analogy to fluorescent dyes used for optical imaging studies99' 100. Earlier efforts to create
MRI sensors have focused on incorporating traditional MRI contrast moieties, such as
gadolinium chelates or iron oxide nanoparticles, into complex organic structures or
supramolecular assemblies 100, resulting in sensors that are difficult to engineer,
synthesize and apply in vivo.
Neurotransmitters are prime targets for sensing by new MRI imaging agents.
Dopamine (DA) is a neurotransmitter of particular interest because of its role in learning,
reward and motor coordination 37. Dysfunction of dopaminergic systems is implicated in
addiction 38 and neurodegenerative diseases 39. Most measurements of DA release in basic
research rely on invasive techniques like microdialysis 40 and voltammetry4 1, which report
variations of DA concentration at a single site in the brain. Positron emission
tomography (PET) is used to monitor DA receptor occupancy and related variables42.
PET methods are sensitive, but have relatively low spatial resolution (> 1 mm); and
because most PET measurements are based on kinetic modeling, they are best suited to
studies of chronic conditions or temporal changes that occur on the time scale of many
minutes or longer. To build an understanding of how DA functions in brain processing,
there is therefore a need to develop measurement techniques that could be applied at a
whole-brain level, and that have significantly better spatial and temporal resolution than
PET. MRI, in combination with a suitable contrast agent sensor, would help satisfy this
need.
No MRI contrast agent for sensing DA (or any other neurotransmitter) has been
reported to date, and the specifications for such an agent are strict. DA fluctuations in the
basal ganglia of the brain, for instance, take place on the order of seconds, and involve
peak DA concentrations < 100 pM43' 4. A DA sensor must therefore respond quickly,
reversibly, and specifically to DA fluctuations in the micromolar range. To be
comparable with established functional brain imaging techniques (fMRI), the probe must
45
also be capable of producing image signal changes in tissue on the order of 1% or more4.
Metalloproteins represent a promising platform for engineering MRI sensors of DA
and other small molecules. Many metalloproteins are natural MRI contrast agents
because they contain paramagnetic ions that interact with water molecules to accelerate
nuclear magnetic T, or T2 relaxation rates, in turn brightening or darkening (respectively)
MRI image intensities. Proteins typically offer ample surface area for achieving
specificity in ligand binding, are straightforward to produce and deliver exogenously, and
may also be delivered indirectly as genes. A variety of rational and evolution-based
methods have been developed to engineer protein function. The paramagnetic
flavocytochrome protein P450-BM3 from Bacillus megaterium (BM3) has become a
platform for efforts to tune catalytic activity using so-called "directed evolution"
techniques, involving multiple rounds of mutagenesis and high throughput screening.
Because of the ease with which its substrate range can be altered, BM3 is an especially
promising starting point for engineering of new MRI sensors. We show here that by
applying a novel directed evolution approach to BM3, we have been able to isolate MRI
contrast agents suitable for DA sensing in vivo.
RESULTS
Natural and unnatural ligand binding to the BM3 heme domain changes MRI
contrast and optical absorption in a concentration-dependent manner
The wild-type BM3 enzyme is a soluble fatty acid hydroxylase comprising a 53
kDa heme domain fused to a 65 kDa reductase domain. The heme domain (BM3h)
contains a single paramagnetic iron(III) atom (mixed spin 1/2 and 5/222), bound to a
hemin prosthetic and axially coordinated by residue C399 on the protein. In the absence
of substrate, the remaining iron coordination site is filled by a water molecule23.
Interaction between exchanging water molecules at the axial site and the heme iron atom
promotes T1 relaxation in aqueous solutions . To determine the extent of this effect, we
used a spin echo MRI pulse sequence to measure the proton relaxation rate as a function
of protein concentration in phosphate buffered saline solution (PBS); the slope of this
relationship (T relaxivity, or r1) provides a standard measure of the strength of a contrast
agent. For BM3h in the absence of ligands, an ri value of 1.23 ± 0.07 mM-'s-I was
obtained. Addition of a saturating quantity of natural BM3 substrate, arachidonic acid
(AA, 400 uM concentration), resulted in an r1 of 0.42 ± 0.05 mM-'s' (Fig. la). This
ligand-dependent change in relaxivity enabled quantitative sensing of AA using MRI
(Fig. 1b), and suggests that BM3h could serve as a platform for molecular sensor
engineering.
We next tested whether DA or related compounds could serve as unnatural ligands
to BM3h, when applied at high enough concentrations. As measured by MRI, addition of
1 mM DA to BM3h in fact induced a drop in ri, to 0.76 ± 0.03 mM- s-1. (Fig Ia).
Binding of AA is known to induce a change (blue shift) in BM3h's optical absorbance
spectrum, because of perturbation of the electronic environment of the heme
chromophore 01 . To determine whether low affinity binding by DA also influences
optical absorption by BM3h we measured spectra in the presence and absence of 1 mM
DA. The interaction produced a significant red shift of Anax, from 419 to 422 nm (Fig.
1 c). Red shifting of iron porphyrin absorption spectra has been taken to indicate direct
coordination to the heme iron 01, and suggested in this case that 1 mM DA directly
replaces water as an axial metal ligand in BM3h; this model is consistent with the
established propensity of catechols to bind to iron and other transition metals. These
considerations strongly suggested that MRI and optical readouts of ligand binding to
BM3h both report interactions with the heme site, and that binding measurements
obtained with either modality are comparable indicators of these interactions. We
monitored the difference between absorption at two wavelengths, as a function of ligand
concentration, to determine binding isotherms for AA and DA (Fig 1 d,e). For BM3h,
the apparent Kd for AA was 6.8 ± 0.5 pM; for DA the Kd was 990 ± 110 pM. Goals for
the production of BM3h-based MRI sensors thus included decreasing the affinity for AA,
increasing the DA affinity by at least two orders of magnitude, and maintaining or
enhancing the relaxivity changes observed upon ligand binding.
Screen-based isolation of BM3h mutants with enhanced DA affinity
To create an MRI sensor for DA using directed evolution, we needed to develop a
customized screening methodology (Fig. 2a). Results presented above suggested that
either MRI-based or optical assays could be used conveniently to distinguish BM3h
mutants with differing ligand affinities. We chose to use an absorbance assay for our
screen, primarily because low protein concentrations (-1 M) could be used for affinity
measurements. Input to each round of screening consisted of a library of BM3h mutants
generated by error-prone PCR from the wild-type gene or a previously selected mutant.
DNA libraries of ~1015 variants each were transformed into E. coli and plated.
Approximately 900 randomly selected clones were grown and induced in microtiter plate
format, then prepared into cleared lysates for optical assaying in a plate reader. Aliquots
of DA and AA were then added to lysates while optical spectra were recorded. High-
throughput fluid handling was achieved using an automated pipetting station. The optical
data was analyzed to determine Kd values for DA and AA. An average of 79% of
assayed mutants exhibited sufficient protein levels (absorbance signal > 30% of parent)
and had clean enough titration curves (r2 > 0.8) for Kd estimation. Mutant affinities
appeared to be distributed randomly about the dissociation constant measured for the
corresponding parent protein; however individual clones with significant desired affinity
changes could be identified in each round (Fig. 2b). From each screen, 8-10 mutants
were chosen based on their estimated Kd's, purified in bulk, re-titrated to obtain more
accurate estimates of DA and AA affinities, and examined by MRI to ensure that robust
ligand-induced changes in ri could be detected. Based on these assays, the mutant
showing the best combination of improved DA affinity, decreased affinity for AA, and
relaxivity changes was chosen to be a parent for the next round of directed evolution.
By carrying out the screening strategy over multiple rounds, we found a steady
trend in the distribution of Kd values towards greater affinity for DA and lower affinity
for AA (Fig. 2b-d). Little change in binding cooperativity was observed, and changes in
partial saturation generally occurred over a factor of 100 in DA concentration. Five
rounds of evolution yielded a BM3h variant with eight mutations (Fig. 2e), four near the
ligand-binding pocket and four at distal surfaces of the protein. One residue (1263) was
first mutated to threonine (third round), then to alanine (fourth round). The clones
selected from rounds one, three and five had two new mutations each. We did not
perform site-directed mutagenesis to determine the relative contribution of each mutation
to the observed changes in affinity. The mutation 1366V was introduced by site-directed
mutagenesis after the fourth round to enhance thermostability 102, 103 (see supplementary
materials).
Selected sensor proteins show strong, preferential MRI response to DA
The mutant proteins selected after the fourth and fifth round of evolution, denoted
BM3h-8C8 and BM3h-B7, had dissociation constants of 8.9 ± 0.7 pM and 3.3 ± 0.1 pM,
respectively, for DA, and 750 ± 140 gM and 660 ± 80 gM for AA. The T1 relaxivity of
BM3h-8C8 was 1.1 ± 0.1 mM-1s-' in the absence of ligand, and 0.17 ± 0.03 mM-1s-1 in the
presence of 400 pM DA (Fig. 3a). For BM3h-B7, the corresponding ri values were 0.96
± 0.13 mM-'s-1 and 0.14 ± 0.04 mM-'s- . Both sensor variants exhibited a DA
concentration-dependent decrease in Ti-weighted MRI signal (up to 13% with 28.5 PM
protein) that could be fitted by binding isotherms with estimated Kd values of 4.9 ± 2.7
tM for BM3h-8C8 and 2.7 ± 2.9 pM for BM3h-B7 (Fig. 3b,c).
The reporting specificities of BM3h-8C8 and BM3h-B7 for DA were investigated
by measuring MRI signal changes that resulted from incubating 28.5 pM of each protein
with 30 pM of DA or one of eight other neuroactive molecules: norephinephrine (NE),
3,4-dihydroxy-L-phenylalanine (DOPA), serotonin (5HT), glutamic acid (Glu), glycine
(Gly), y-aminobutyric acid (GABA), acetylcholine (ACh), and AA (Fig. 3d). Of these
potential ligands, only DA, NE and 5HT elicited significant changes in the T, relaxation
rate (1/TI). For BM3h-8C8, the 1/T1 reductions produced by NE and 5HT were 0.0076 ±
0.0023 s-i and 0.0041 ± 0.0020 s-1, respectively, compared to 0.0182 ± 0.0006 s-1 for DA;
for BM3h-B7, NE and 5HT induced 1/T1 decreases of 0.0112 ± 0.0024 s-1 and 0.0171 ±
0.0005 s-1, respectively, compared to 0.0208 ± 0.0002 s-1 for DA. The affinities of BM3h-
based DA sensors for these competitors were measured spectroscopically (Fig. 3d, inset).
For BM3h-8C8, measured Kd's were 44 ± 3 pM and 80 ± 8 pM for NE and 5HT,
respectively, and for BM3h-B7 the Kd values were 18.6 ± 0.4 pM and 11.8 ± 0.1 pM,
respectively. While both BM3h-8C8 and BM3h-B7 show significantly higher affinity for
DA over NE (5-fold and 6-fold, respectively) and over 5HT (9-fold and 4-fold,
respectively), the BM3h-8C8 variant is more specific for sensing DA at concentrations
above 10 pM. In settings where DA is known to be the dominant neurotransmitter,
BM3h-B7 may provide greater overall sensitivity
The stability and reversibility of DA sensing by BM3h variants were examined.
DA-induced changes in the BM3h-B7 and BM3h-8C8 absorbance spectra were steady
over a period of more than 2 hours, in the presence of DA concentrations up to 800 pM
(Supplementary Fig. 1). Reversibility of DA binding to the sensors was confirmed by
showing that their absorbance spectra reverted to their ligand-free state after DA was
removed by size-cutoff filtration (Supplementary Fig. 2). Stored in PBS at 4' C, the
proteins appeared stable over a period of several days.
BM3h-based sensors report DA release from PC12 cells in vitro
We next asked whether BM3h mutants identified by directed evolution could sense
DA release from living cells. The pheochromocytoma cell line PC 12 provides a popular
model of DA metabolism, transport, and signaling' 04 ; PC 12 cells have been shown to
release vesicular DA when depolarized by extracellular potassium ions105 . We therefore
adapted an established experimental paradigm to test the ability of our sensors to detect
stimulus-evoked DA discharge from PC12 cells (Fig. 4a). Cells were loaded with DA by
preincubation over a one hour period. After pelleting and washing, cells were
resuspended in a physiological buffer containing 32 pM BM3h-B7 and either 5.6 or 59.6
mM K* (the low K* condition was osmotically balanced with Nat). Ti-weighted MRI
images (spin echo TE/TR = 10/477 ms) obtained with BM3h-B7 showed a 4.0 ± 0.5%
reduction in signal intensity in the supernatant of K*-stimulated cells, compared with
cells for which isotonic Na* was used as a nondepolarizing control stimulus (Fig. 4b).
This corresponded to a 54 ± 4% decrease in sensor ri (Fig. 4c). Given the DA
dissociation constant of BM3h-B7 and its relaxivities under ligand-free and DA-saturated
conditions, and assuming negligible dilution of the sensor after mixing with cells, we
estimated supernatant DA concentrations of 50.7-63.7 ptM for stimulated cells and 21.0-
23.2 pM for controls. These estimates are in reasonable agreement with an independent
quantification of DA release made using an enzyme-linked immunosorbent assay
(ELISA), which yielded concentrations of 54 ± 9 pM and 13 ± 2 pM for stimulated and
control cells, respectively (Fig 4d). BM3h-8C8 could also be used to image DA release
from PC12 cells. Under experimental conditions similar to above, BM3h-8C8 exhibited a
37 ± 2% reduction in ri in the supernatant of K*-stimulated cells relative to Na* controls
(Supplementary Fig 3). These results demonstrated that BM3h-based sensors are capable
of reporting release of DA in a biological context using MRI.
BM3h-8C8 enables dynamical MRI imaging of DA transport in vivo
To demonstrate sensing in vivo, we used BM3h-8C8 to image the transport of
injected DA in the striatum of anesthetized Lewis rats. We first confirmed that the
interaction between DA and BM3h-8C8 produces the expected MRI contrast change in
the in vivo environment. The sensor, alone or mixed with DA, was infused
stereotactically into rat striatum over 20 minutes (Fig. 5a). Images were obtained before,
during and after infusion using a Ti-weighted FSE pulse sequence with a spatial
resolution of 0.3 mm x 0.3 mm x 1 mm and a temporal resolution of 8s. The 15 voxels
with the greatest change in signal at the end of the infusion period were selected for
further analysis. As expected, infusing BM3h-8C8 produced a gradual increase in Ti-
weighted signal (to ~ 25% at the end of the infusion period), the magnitude of which was
reduced to -10 % by co-infusing DA (Fig 5b, c). Infusing wild-type BM3h also produced
a signal change, but this change was unaffected by the presence of DA (Fig 5d).
Since the striatum is heavily innervated by dopaminergic axons, some amount of
reuptake would be expected for DA infused into this brain region. We hypothesized that
reuptake of DA could contribute to higher TI-weighted signal by removing some DA that
would otherwise be bound to BM3h-8C8. In preliminary experiments to test this
hypothesis, we endeavored to block DA reuptake using cocaine. When cocaine was co-
infused into the striatum together with BM3h-8C8 and DA, both the maximal signal
change and the rate of signal increase during infusion were significantly reduced (Fig 5e),
suggesting that more DA remains in the selected voxels, although additional experiments
are needed to confirm that this is the case. These results demonstrate that BM3h-8C8
retains its DA-dependent contrast properties in vivo and could potentially serve as an
effective sensor of DA transport in the living brain.
DISCUSSION
Our results demonstrate for the first time that a powerful protein engineering
method can be applied successfully to the construction of a dynamic MRI sensor capable
of imaging an important signaling molecule in vivo. Instrumental to the success of our
approach was the choice of a protein, cytochrome P450 BM3h, which produced ligand-
induced MRI contrast changes in its wild-type form and had tunable ligand selectivity,
making it a suitable platform for sensor development. To apply directed evolution to the
creation of a DA sensor, we designed an optical screen for mutant proteins with enhanced
DA sensitivity. Although an MRI-based screen might have been more direct, the optical
titration curves we in fact examined could be measured more conveniently, and appeared
to be directly correlated with relaxivity-determining structural changes near the protein's
heme site. This methodology can be employed to develop sensors for a variety of small
molecules, with a wide structural range implied by our ability to tune sensing between the
structurally dissimilar molecules AA and DA.
In vitro experiments confirmed that the high-affinity DA sensors we produced,
BM3h-B7 and BM3h-8C8, are able to detect and quantify depolarization-triggered DA
release from cultured cells. Given the IIT1 changes we observed in this context (-0.01 s-
), it is reasonable to expect signal changes of -1-2% to be observed if the sensors are
applied at similar concentrations in the extracellular space of the intact brain, and if DA
concentrations varied in the range from 0-40 pM DA (as in brain stimulation reward
paradigms, e.g. 43'44).
In vivo, we demonstrated that BM3h-8C8 could be used to observe signal changes
resulting from co-infusion of DA in the rat striatum and potentially from modulation of
its reuptake with cocaine. These observations was aided by the high spatial (300 pim) and
temporal (8 sec) resolution of MRI, highlighting one of the major advantages of sensors
designed for this imaging modality.
Detection by MRI would be easier if the sensors had higher ri. At field strengths
comparable to the 4.7 T we used, relaxivity changes of roughly 1.8 to 2.5 mMIs-1 have
been reported for Gd -based synthetic sensors14' 106, which have higher electron spin (S
7/2) than BM3h (mixed S = 1/2, 5/2). In principle, improved BM3h sensors for DA or
other ligands could be engineered to produce greater relaxivity changes, most likely by
increasing the percentage of high spin iron in the heme site.
In future studies, BM3h-based sensors for DA may be applied by direct intracranial
infusion as was done here, or intravenously in conjunction with blood-brain barrier
permeabilization techniques 107. Subsequent monitoring of DA release and transport will
be valuable in studies of reward, addiction, Parkinson's disease, and a variety of brain
phenomena involving dopaminergic signaling; related sensors could be applied in similar
ways to study additional neurotransmitter systems or physiological phenomena. Because
BM3h-based MRI sensors are proteins, they may also be targeted genetically to specific
brain regions or cell types' 08, where they would report local analyte concentrations,
provided that high enough sensor expression levels (> 10 pM) could be attained. A
longer-term motivation behind the development of novel MRI sensors is the potential for
human diagnostic use, either as exogenous agents or components of genetically-
engineered transplants such as stem cells. The relative ease of production and versatility
of metalloprotein MRI sensors, like the DA probes introduced here, suggests that this
new class of reagents may find utility in a broad range of biological and medical
applications.
METHODS
Library construction
BM3h mutant libraries were constructed in accordance with a previously published
protocol25 . The starting parent for evolution was the wild type heme domain of BM3 with
a C-terminal hexahistidine tag, housed in the pCWori vector109 . Mutant libraries were
constructed through error-prone PCR using the primers
GAAACAGGATCCATCGATGCTTAGGAGGTCAT (forward) and
GCTCATGTTTGACAGCTTATCATCG (reverse) and Taq polymerase (AmpliTaq,
Applied Biosystems, Foster City, CA) with 25 pM MnCl 2, producing approximately 1-2
mutations per gene. Between the fourth and fifth rounds of evolution, the mutation
1366V was introduced into 8C8 via overlap extension PCR to improve protein
thermostability 0 3 (see Supplementary Info).
Protein expression and high-throughput screening
Mutant colonies were picked into deep-well 96-well plates containing 0.4 mL Luria
Broth (LB) medium and grown overnight. On each plate, the parent clone and up to three
previous parents were included in triplicate. 0.1 mL of each culture was transferred to
new plates containing 1.2 mL fresh Terrific Broth (TB) medium per well, supplemented
with 100 pg/mL Ampicillin, 0.2 mM IPTG and 0.5 mM 6-aminolevulinic acid (ALA).
Remaining LB cultures were stored with glycerol at -80 'C. Following 20-30 hours of
protein expression at 30 'C, cultures were pelleted and lysed in 0.65 mL PBS containing
0.75 mg/ml hen egg lysozyme (Sigma Aldrich, St. Louis, MO) and 5 pg/mL DNase I
(Sigma Aldrich). Absorbance spectra of 200 pL of cleared lysate from each well were
recorded in a multiwell plate reader (Spectramax Plus, Molecular Devices, Sunnyvale,
CA ) before and after addition of successively more concentrated DA or AA. The
resulting absorbance spectra were analyzed in Matlab (Mathworks, Natick, MA), using a
custom routine that calculated the absorbance difference spectra for each acquisition
relative to ligand-free lysate, computed the difference between maximum and minimum
of each difference spectrum, plotted each value as a function of ligand concentration, and
for each well fitted a non-ligand depleting bimolecular association function to estimate
the corresponding Kd. Mutant Kd values were compared to those of the parents within
each plate, and 8-10 mutants showing the greatest decrease in Kd for DA and/or the
greatest increase in Kd for AA were chosen for bulk expression and analysis.
Bulk expression and titrations
Frozen LB cultures of selected mutants were inoculated into 30 mL TB medium
containing 100 tg/mL Ampicillin, induced at log phase with 0.6 mM IPTG,
supplemented with 0.5 mM ALA and 50 pg/ml thiamine, and shaken for an additional
20-25 hours to express protein. Pelleted cells were lysed with BugBuster and Lysonase
(EMD Chemicals, San Diego, CA) and BM3h mutants purified over Ni-NTA agarose
(Qiagen, Valencia, CA). Buffer was exchanged to PBS over PD-10 desalting columns
110(GE Healthcare, Piscataway, NJ). Protein concentration was measured by CO assay".
Titrations with DA, AA, 5HT, NE, DOPA, Ach, Glu, Gly, and GABA (Sigma Aldrich)
were performed on samples of purified protein and analyzed using Matlab as described
above.
MRI
Samples (60-100 pL) were arrayed into microtiter plates and placed in a 40-cm-
bore Bruker (Billerica, MA) Avance 4.7 T MRI scanner, equipped with a 10 cm inner
diameter birdcage resonator radiofrequency coil and 26 G/cm triple axis gradients.
Unused wells of the microtiter plates were filled with phosphate buffered saline, and
imaging was performed on a 2-mm slice through the sample. A Ti-weighted spin echo
pulse sequence was used; echo time (TE) was 10 ins, and repetition times (TR) ranged
from 77 ms to 5 s. Data matrices of 512 x 128 points were acquired and zero-filled to
1024 x 512 points, where the second dimension corresponds to the phase encoding
direction. Images were reconstructed and analyzed using custom routines running in
Matlab. Relaxation rates and relaxivities reported here were calculated by exponential
fitting to the image data. Contrast was adjusted to produce MRI images presented in the
figures.
DA release from PC12 cells
PC12 cells were grown in suspension in F-12K medium supplemented with 15%
horse serum and 2.5% fetal bovine serum (ATCC, Manassas, VA). In preparation for DA
release experiments, 50 mL cell cultures were incubated for one hour in medium
supplemented with 1 mM DA and 1 mM ascorbic acid, pelleted and washed twice with
Locke's buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO 3, 2.3 mM CaCl2, 5.6 mM
D-glucose, and 5 mM HEPES, pH 7.4). To Locke's buffer missing 54 mM NaCI and
containing or not containing the sensor, a 1:50 dilution of 2.7 M KCl (stimulus) or NaCl
(control) was added. Washed PC 12 cell pellets were resuspended in 200 pL of either K*-
or Nat-supplemented buffer, with or without sensor. After 30-60 minutes incubation at
room temperature, cells were pelleted and the supernatant was imaged in an MRI scanner
as described above. DA release was estimated by calculating sensor saturation level from
observed ri, then solving the quadratic equation describing bimolecular equilibrium
binding with a known Kd, and assuming 32gM of sensor, for ligand concentration.
Independent measurements of DA release were made using the Dopamine EIA Kit (LDN,
Nordhorn, Germany).
MRI imaging of DA transport in vivo
Lewis rats (350-500 g) were anesthetized with 1.5% - 2% isoflurane, placed on a
heat blanket and monitored with pulse oxymetry throughout the subsequent surgery.
Plastic guide cannulae (6 mm length, PlasticsOne) were stereotactically inserted
bilaterally into the striatum using stereotactic coordinates (0.7 mm rostral and 3 mm
lateral to bregma, 5 mm below dura) and secured in place with dental cement. A T-
shaped headpost (Ultem 1000) was subsequently cemented on to the skull rostrally to the
guide cannulae. Plastic tubing filled with silicon oil was connected to an MRI-compatible
dual channel syringe pump (PhD 2000, Harvard Apparatus). The Silicon oil was retracted
to generate a small air cushion of about 1 pl at the tips before connecting the internal
cannulae (6.1 mm length, PlasticsOne) to the tubing. Subsequently, a volume of 20 pl of
PBS solution containing the MRI sensor (500 pM 8C8 variant (or wt) of BM3h +/- 500
pM of Dopamine (Sigma) ) was aspirated through the internal cannulae. The solution for
the cocaine reuptake inhibition experiments contained 500 gM 8C8 variant, 500 pM and
+/-
1 ptmole cocaine (Sigma). The pump was then slowly run in infusion mode for a short
time to ensure that the MRI sensor solution would reach the tip of the cannulae without
any dead space. Internal cannulae were subsequently inserted into the guide cannulae and
secured with dental cement. A MRI surface coil (Insight Neuroimaging), modified to
have an appropriate cutout to accommodate the cannulae and the headpost, was placed
over the rat's head. The head was then moved into a plastic headgear, the rat's teeth
positioned over a bite bar and the headpost screwed into the headgear with plastic screws.
Subsequently, the rat was moved into a body holder, which was wrapped in a heat
blanket before being inserted into a birdcage body coil (Insight Neuroimaging). The dual
coil imaging setup was then moved in to the bore of a Bruker 4.7 Tesla magnet (40 cm
horizontal bore) interfaced to an AVANCE console (Bruker Instruments) and equipped
with a 12 cm ID triple axis gradient set (26 G/cm maximum). The scanner was controlled
using Paravision software running on a Linux workstation. A continuous series of MRI
scans were obtained using a Ti-weighted FSE pulse sequence (0.3 mm x 0.3 mm x 1 mm
resolution, 8 s per image) before, during and after an injection period of 20 minutes
(0.0005 mL/min). The rat was monitored by pulse oxymetry throughout the imaging
experiment. Analysis of imaging data was performed with Matlab v.7 (Mathworks)
running in-house processing routines.
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FIGURE LEGENDS
Figure 1. Ligand binding to the BM3 heme domain changes MRI contrast and optical
absorption in a concentration-dependent manner. (a) Ti relaxivity (ri) of BM3h in PBS
solution, and in the presence of 400 pM AA or 1 mM DA; inset shows Ti-weighted spin
echo MR image intensity (TE/TR = 10/477 ms) of microtiter plate wells containing 240
pM BM3h in PBS alone (left), or in the presence of 400 pM AA (middle) or 1 mM DA
(right). (b) T1 relaxation rates (1/T1) measured from solutions of 28.5 gM BM3h
incubated with 0-250 pM AA. (c) Optical absorbance spectra of 1 pM BM3h measured
alone (blue), and following addition of 400 pM AA (gray) or 1 mM DA (orange). (d)
Difference spectra showing the change in BM3h absorbance as a function of wavelength
upon addition of 400 pM AA (gray) or 1 mM DA (orange). (e) Normalized titration
curves showing binding of BM3h to AA (gray) or DA (orange). The optical signals used
for titration analysis were formed by subtracting the minimum from the maximum of
difference spectra [arrowheads in (d)] under each set of conditions. Error bars were
smaller than the symbols.
Figure 2. Screen-based isolation of BM3h mutants with enhanced DA affinity. (a)
Schematic of the directed evolution approach, including (left to right) mutant DNA
library generation, transformation into E. coli and growth in multiwell plate format,
spectroscopic analysis of each mutant's ligand binding affinities, and detailed MRI and
optical characterization of selected mutant proteins. (b) Histograms of mutant DA
dissociation constants determined during each round of directed evolution, by relating
each mutant protein's relative DA affinity (measured in plate format) to the Kd of the
parent protein (measured in bulk). Kd distributions for screening rounds one (blue), two
(green), three (red), four (cyan), and five (purple) are labeled by numbers in circles.
Color-coded arrowheads indicate the measured Kd's of parent proteins used to create the
library of mutants at each round; the yellow arrowhead indicates the Kd of the mutant
protein selected after round five of screening. (c) Dissociation constants for DA (orange)
and AA (gray) measured from wild type BM3h and mutant BM3h variants isolated by
each round of screening; progressive improvements in DA affinity and attenuation of AA
affinity are evident. Colored arrowheads indicate the correspondence with data in panel
(a). (d) Titration analysis of DA binding to WT BM3h and proteins selected after each
round of directed evolution [color coding as in (b)]. Mutant proteins identified by rounds
four (8C8) and five (B7) were considered to be end products of the screening procedure.
(e) X-ray crystal structure111 of WT BM3h (gray; heme group shown in orange) bound to
palmitoleic acid (black), indicating the location of amino acid substitutions accumulated
during directed evolution of enhanced DA binding affinity. Each mutation's location is
identified by a blue sphere and a label color-coded by the parent protein in which the
substitution was first identified [see caption to (b)]. The previously characterized 1366V
mutation (asterisk) was incorporated between screening rounds four and five, to improve
the thermostability of the engineered proteins.
Figure 3. Selected sensor proteins produce strong and specific MRI signal changes in
response to DA. (a) Relaxivity values measured from BM3h-B7 (yellow bars) and
BM3h-8C8 (purple bars) in PBS alone, or in the presence of 400 pM DA. The inset
shows TI -weighted MRI signal (TE/TR = 10/477 ms) obtained from 195 pM BM3h-B7 or
BM3h-8C8, each incubated in microtiter plate wells with or without 400 pM DA (wells
ordered left to right as in the bar graph). (b) A normalized MRI image showing signal
amplitudes measured from wells containing 28.5 p.M WT BM3h, BM3h-8C8, and BM3h-
B7, each incubated with increasing DA concentrations (0-63 gM, left to right). The
image was formed by dividing signal from a Ti-weighted scan (Ir,; TE/TR = 10/477 ms)
by signal from a proton-weighted image (I H; TE/TR = 10/5000 ms), to correct for
intensity variation due to radiofrequency heterogeneity in the scanner. (c) Relaxation
rates (1/T1 values) measured from solutions of 28.5 pM WT (blue), BM3h-B7 (yellow),
and BM3h-8C8 (purple), as a function of total DA concentration. Curves were fitted
using a ligand-depleting bimolecular association model. (d) Changes in IT 1 relative to
ligand-free protein for 28.5 pM BM3h-B7 (yellow) and BM3h-8C8 (purple) incubated
with 30 pM DA, 5HT, NE, DOPA, AA, ACh, GABA, Glu, or Gly; inset:
spectroscopically determined affinities (Ka = 1/Kd) of BM3h-B7 and BM3h-8C8 for DA,
5HT, and NE.
Figure 4. BM3h-based sensors report DA release from PC12 cells. (a) In our
experimental paradigm, PC 12 cells depolarized by addition of 54 mM K, but not 54 mM
Na*, were stimulated to release DA into supematants containing a BM3h-based sensor.
(b) Ti-weighted spin echo MRI signal amplitudes (TE/TR = 10/477 ms) measured from
the supernatants of PC12 cells incubated with 32 pM BM3h-B7 in the presence of K*
(stimulus) or Na* (control); inset: MRI image of microtiter wells under corresponding
conditions. (c) Relaxation rates measured from the samples in (b), minus the relaxation
rate of buffer not containing BM3h-based sensors. Given the approximate concentration
of BM3h variants in these samples, the A(1/T 1) values correspond to apparent relaxivities
of 0.23 and 0.50 mM-'s-' in K* and Na* incubation conditions, respectively. (d) Data
from panel (c) were used to estimate the concentrations of DA present in samples treated
with K* and Na* (gray bars). Independent measurement of [DA] under equivalent
conditions was performed using an ELISA assay (white bars).
Figure 5. BM3h-8C8 enables dynamical MRI imaging of DA transport in vivo. (a)
Diagram of setup for in vivo infusions. Bilateral injections into the striatum were made
via surgically implanted cannulae. For ± DA experiments, BM3h-8C8 or wild type BM3h
was injected on both sides, with DA co-injected on one side. For ± cocaine experiments,
BM3h-8C8 and DA were co-injected on both sides, and cocaine was co-injected on one
side. (b) Ti-weighted MRI image of three adjacent coronal slices at the end of a BM3h-
8C8 ± DA injection. Cannulae tracts are visible in the middle slice. A brightening of the
image is observed immediately below the tip of the right cannula, where sensor was
injected alone, but not below the tip of the left cannula, where DA was co-injected with
sensor. (c) Timecourse of TI-weighted signal change during and after injection of BM3h-
8C8 without (blue) and with (orange) DA. Gray shading indicates when the injection
occurred. (d) Same as (c), but with wild type BM3h instead of BM3h-8C8. (e)
Timecourse of signal during injection as in (c), but both with both sides receiving BM3h-
8C8 and DA, without (orange) or with (green) the addition of I pmol cocaine.
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SUPPLEMENTARY MATERIAL
DA binding to BM3h-B7 and BM3h-8C8 is stable and reversible
The stability of DA binding to BM3h-B7 and BM3h-8C8 was tested by incubating
each protein with various amounts of DA at room temperature and measuring the
absorbance difference at 430 nm and 410 nm over two hours (Supplementary Fig. 1).
During this time, a decline of less than 5% was observed when 1 PM sensor was
incubated in the presence of excess DA (800 ptM). Optical changes were greater when
sensor was incubated with subsaturating concentrations of DA (up to 22% signal change
for 1.3 gM DA incubated with BM3h-B7), consistent with the predicted effects of DA
oxidation (known to take place under ambient conditions) on the partial saturation of the
sensor. To test the reversibility of DA binding to BM3h-B7 and BM3h-8C8, we acquired
absorbance spectra of the proteins alone and with 400 ptM DA before and after filtering
the solutions through a 30 kDa cutoff centrifugal filter. Successive steps of filtering and
resuspension restored the original, ligand-free spectrum (Supplementary Fig. 2a,b).
Thermostabilization of BM3h-8C8
Mutations in the amino acid sequence of BM3h have been shown to reduce the
protein's thermostability. This was observed during directed evolution of BM3h: the
melting temperature (Tm, the midpoint temperature for thermal denaturation after 10 min)
of WT BM3h was approximately 58 'C, while the Tm for BM3h-8C8 was approximately
48 'C. While this change did not significantly affect the protein's stability in physiologic
buffer at room temperature, it did apparently reduce the yield of our bulk purification
procedure. To improve thermostability of BM3h-8C8 before performing the fifth round
of evolution, we introduced the mutation 1366V, which has been shown previously to
improve stability102 . For BM3h-8C8 this improvement corresponded to a T increase by
approximately 4 'C.
SUPPLEMENTARY FIGURE CAPTIONS
Supplementary Figure 1. Optical signatures of DA binding to BM3h-B7 (a) and
BM3h-8C8 (b) are stable over two hours. Absorbance at 430 nm minus 410 nm collected
over 2 hrs. for 1 pM sensor incubated in the presence of 0-800 iM DA (labels in color).
Supplementary Figure 2. DA binding to BM3h-B7 and BM3h-8C8 is reversible. (a)
Absorbance spectra of 1 pM BM3h-B7 alone (blue) or incubated with 400 PM DA
(green) before filtering (top), and after filtering twice (middle) or three times (bottom)
through a 30 kDa cutoff filter. (b) Ratios of absorbance at 430 nm to 410 nm
corresponding to the DA-free (white bars) and DA-incubated (gray bars) spectra in (a).
Panels (c) and (d) display equivalent data for sensor variant BM3h-8C8.
Supplementary Figure 3. BM3h-8C8 reports DA release from PC12 cells. Plot and
experimental conditions are analogous to Fig. 4c in the main text.
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4. Protein nanoparticles engineered to sense
protein kinase activity in MRI
ABSTRACT
Discoveries in neuroscience would be aided by the creation of tools for non-invasive
molecular imaging of the brain, but the development and application of imaging agents
that could serve this purpose remains a major challenge. Nanoscale superparamagnetic
materials have been used to create molecular sensors for magnetic resonance imaging
(MRI), but their synthetic nature makes them challenging to produce and limits their
potential for future use in vivo. Here we describe for the first time a completely protein-
based molecular sensor made of self-assembling multifunctional nanoparticles
incorporating the iron storage protein ferritin. We created a sensor for cAMP-dependent
protein kinase A (PKA), a key signaling molecule involved in memory processes, by
generating fusions of ferritin with domains of CREB and CBP, and co-expressing them in
mammalian cells with wild type and epitope-tagged ferritin subunits. Intact self-
assembled nanoparticles were easily purified and loaded with iron. Incubation with PKA
induced aggregation of the sensor nanoparticles, leading to real-time T2 contrast
enhancement in MRI. Our approach enables future work towards genetically engineered
molecular sensors for a variety of signaling processes, with potential applications in basic
research and clinical diagnostics.
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INTRODUCTION
Magnetic resonance imaging (MRI) has been a powerful tool in biological research,
offering non-invasive access to anatomy and activity at high spatial and temporal
resolution 7. However, the range of biological phenomena accessible to measurement by
MRI is limited due to a lack of molecular sensors that can respond dynamically to
specific molecular signaling events. Earlier efforts to create MRI sensors have
incorporated traditional MRI contrast moieties, such as gadolinium chelates or iron oxide
nanoparticles, into complex organic structures or supramolecular assemblies 99, 100,
resulting in sensors that are difficult to engineer, synthesize and apply in vivo.
MRI sensors based on proteins could resolve some of these difficulties. They could
be developed using well-established protein engineering methods. They could be
synthesized easily in cultured cells. And they could be applied in vivo by direct delivery
or in-situ synthesis in cells targeted with corresponding genetic constructs.
The iron storage protein ferritin (Ft) represents a potential platform for developing
protein-based MRI sensors. Ft comprises a 12nm protein shell and an 8nm
antiferromagnetic iron oxide core containing up to 4,000 iron atoms 27. Ft induces T2
relaxation in MRI and has been studied as an endogenous source of anatomical contrast
and an exogenous marker of gene expression 28-30. Aggregation of Ft after proteolysis3 1 or
chemical cross-linking32 has been shown to enhance its T2 contrast, suggesting that Ft-
based sensors could be made analogously to those previously created using synthetic iron
oxide nanoparticles 5 ' ' . In these designs, nanoparticle surfaces were functionalized
with moieties whose binding to each other or to other molecules drives the formation of
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aggregates, altering T2 contrast. Sensor performance depends on nanoparticles' surface
properties, including the number of functional groups per particle and propensity for non-
specific agglomeration. Ft nanoparticles comprise 24 heavy chain (HF) and light chain
(LF) subunits which self-assemble into symmetrical nanoparticles at ratios proportional
to their relative expression levels3 5. The N-termini of LF and HF are exposed at the
nanoparticle surface, and can thus serve as sites for genetic fusion of surface functional
groups36. A combination of fusion constructs and wild-type subunits could hypothetically
be co-expressed at particular ratios to achieve desired surface properties and sensor
performance. Ft's aggregation-dependent MRI contrast, its amenability to surface-
functional fusions, and it ability to self-assemble from independent subunits in a
stoichiometrically-controlled fashion make it a potential platform for protein-based
sensor development.
Cyclic AMP-dependent protein kinase A (PKA) plays a critical role in memory
formation and is an active target of pharmaceutical development 46. It is thus an important
target for molecular imaging. A key substrate of PKA is the transcription factor CREB47 .
When the residue Ser133 of the kinase inducible domain (KID) of CREB is
phosphorylated by PKA, CREB binds to the KIX domain of the activator protein CBP48,
49, turning on transcription of CREB-dependent genes . Phosphorylation-dependent
binding of KID and KIX has been studied extensively, and fluorescent sensors of PKA
activity have been made by fusing these domains to variants of green fluorescent
protein or p-lactamase . No MRI or other non-invasive sensor of PKA activity has
been reported.
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RESULTS AND DISCUSSION
We made a protein-based MRI sensor of PKA activity by producing Ft
nanoparticles that incorporated KID or KIX functional groups on their surface (Fig la).
Fusions of KID, KIX and the affinity tag 3xFLAG were made at the N-terminus of LF
(KID-LF, KIX-LF and FLAG-LF, respectively). 3xFLAG was selected because of its
high negative charge at neutral pH, the presence of which we thought would help reduce
non-specific aggregation between Ft nanoparticles. The linker sequence GTSSEFM,
inserted between each functional group and the N-terminus of LF, was found to produce
well-expressing fusion constructs. Plasmids encoding FLAG-LF, wild-type LF, HF, and
either KID-LF or KIX-LF were co-transfected into HEK-293 cells at pre-determined
ratios. After four days of expression, cells were lysed and Ft nanoparticles were purified
over an anti-FLAG resin. The nanoparticles were iron-loaded by incubation of lysates
with an excess of ferrous ammonium sulfate. Self-assembly of different co-transfected
subunits was confirmed by the presence of corresponding bands on coomassie-stained
gels after FLAG purification (Fig. lb). The relative functional group composition of the
nanoparticles could be controlled by varying the transfection ratios of recombinant Ft
genes.
KID-expressing Ft nanoparticles (KID-NPs) could be phosphorylated by PKA and
de-phosphorylated by lambda protein phosphatase (XPPase). Incubation of pre-
phosphorylated KID-NPs (pKID-NPs) with KIX-expressing Ft nanoparticles (KIX-NPs)
at a 3:2 ratio induced the formation of aggregates, as observed by dynamic light
scattering (DLS). These aggregates showed 4.5-fold larger radii than that observed when
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KIX-NPs were mixed with unphosphorylated KID-NPs (Fig 1 c). Adding PKA to a
mixture of KID-NPs and KIX-NPs resulted in a similar level of aggregation. PKA-
induced aggregation could be prevented by adding a PKA inhibitor. Adding kPPase to a
mixture of pKID-NPs and KIX-NPs also resulted in smaller aggregate sizes (Fig 1c).
Changes in KID-LF phosphorylation under these conditions were confirmed with
subsequent SDS-PAGE and phosphoprotein staining (Fig 1 d).
Non-invasive sensing of PKA activity was performed in a 4.7T MRI magnet using a
spin-echo acquisition sequence. Incubation of the sensor (3:2 ratio of KID-NPs with
KIX-NPs) with PKA for 2 hours produced an increase of ~ 84% in the transverse
relaxivity (r2, calculated by subtracting the T2 relaxation rate of sensor-free buffer) from
0.53 ± 0.06 s 1 to 0.98 ± 0.03 s- (Fig 2a). At an echo time (TE) of 210 msec this
corresponded to a 10.7 ± 1.3 % change in MRI signal intensity. PKA-dependent r2 change
could be prevented by adding a PKA inhibitor (Fig 2a). Similarly, a pre-phosphorylated
sensor mixture had a relaxivity of 0.95 ± 0.10 s-1, which was reduced to 0.49 ± 0.11 s-I in
the presence of kPPase. Dynamical MRI measurements enabled real-time monitoring of
PKA activity, with increases in r2 happening faster with higher concentrations of PKA
(Fig 2b).
Effective performance of the sensor depended on the quantity of functional groups
displayed on the nanoparticle surface and the ratio of KID-NPs to KIX-NPs in the sensor
mixture. When the quantity of transfected KID-LF or KIX-LF plasmid relative to wild-
type and FLAG-LF plasmids was changed from 60% to 40%, 20% or 0% (decreases from
60% were compensated by an equal increase in LF), phosphorylation-dependent effects
on r2 were eliminated (Fig 3a). For particles of a fixed transfection composition, the ratio
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of pKID-NPs to KIX-NPs in the sensor mixture (D:X) influenced the level and dynamics
of aggregation (Fig 3b). Although low D:X ratios (54:1) produce the greatest maximal
signal in the phosphorylated condition, they lose relaxivity after short periods, ostensibly
due to over-aggregation, and show a significant change in r2 in the unphosphorylated
state. A high D:X ratio (;8:1) resulted in little phosphorylation-dependent contrast. A
medium D:X ratio -- 3:2 -- showed the greatest phosphorylation-dependent contrast
change on the 1-2 hour timescale; we therefore used this ratio throughout the rest of this
article.
Our results represent the first in vitro proof of concept for a completely protein-
based MRI sensor incorporating Ft, and suggest a general approach to creating future
sensors for non-invasive molecular imaging through genetically directed self-assembly of
multifunctional protein nanoparticles. To create a novel MRI sensor of PKA activity, we
fused KID, KIX and 3xFLAG functionalities to the Ft light chain and co-expressed the
resulting constructs in mammalian cells at desired ratios, yielding multifunctional Ft
nanoparticles. We demonstrated that the fused functional groups conferred their
properties onto the particles (FLAG purification, KID phosphorylation, de-
phosphorylation), and that PKA caused a mixture of KID- and KIX- functionalized
nanoparticles to aggregate. PKA-induced aggregation produced an 84% change in
transverse relaxivity in MRI, allowing these nanoparticles to act as a dynamic non-
invasive sensor of PKA activity. Comparisons of Ft sensors with different levels of
nanoparticle functionalization and D:X ratios revealed valuable engineering principles
that will aid in optimizing the performance of this sensor and of future sensors of this
type.
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Our ability to apply the traditional protein engineering method of fusion
construction to the design of our PKA sensor and our ability to easily synthesize intact
self-assembled sensor particles through expression in mammalian cells highlight two
advantages of a protein-based approach to MRI sensor development. Future in vivo
applications of this or similar sensors may demonstrate a third potential advantage: ability
to deliver sensors to cells or tissues as either purified molecules or as gene constructs to
be expressed by the target cells.
METHODS
Fusion gene construction
Light-chain Ft fusion constructs were generated using standard molecular cloning
techniques. Original genes encoding human Ft were kindly supplied by Paulo Arosio;
genes encoding rat CREB and mouse CBP were obtained from Michael Greenberg. KID-
LF encodes amino acids 88-160 of CREB, followed by the spacer GTSSEFM, and LF.
KIX-LF encodes amino acids 574-686 of CBP, followed by the same spacer and LF.
FLAG-LF encodes the amino acid sequence MDYKDHDGDYKDHDIDYKDDDDK in
place of KID or KIX. All three constructs and LF and HF were cloned into the pCMV-
Sport vector (Invitrogen, Carlsbad, CA) for expression in mammalian cells under the
CMV promoter.
Ft nanoparticle expression and purification
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Ft nanoparticles were expressed in suspension-cultured HEK-293 cells using the
Freestyle293 system (Invitrogen) in accordance with manufacturer instructions. Plasmids
encoding HF, LF, FLAG-LF and either KID-LF or KIX-LF were mixed and transfected
into cells at pre-determined ratios (by DNA mass). For a 60% functional group
composition, the plasmid mixture contained 60% KID-LF or KIX-LF, 20% FLAG-LF,
10% HF and 10% LF. After four days, cells were harvested and lysed in lysis buffer
(50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 1% Triton X-100, pH 7.4, 6ml per pellet
generated from a 50mL culture) supplemented with a protease inhibitor cocktail (Halt,
Pierce, Rockford, IL). Cleared lysates were supplemented overnight with 2mM Ferrous
Ammonium Sulfate (Sigma) at 4'C. Anti-FLAG agarose (Ez-view, Sigma) was added for
an additional 2 hours. After washing with wash buffer (50mM Tris-HCl, 150mM NaCl,
pH 7.4), the nanoparticles were eluted with 0.1 M glycine at pH 3.5, then quenched with
lOX wash buffer. Prior to subsequent handling, nanoparticles were concentrated using
centrifugal filter units and buffer was exchanged to the assay buffer (10mM HEPES,
150mM NaCl, pH 7.4) using size-exclusion chromatography. Particle concentration was
estimated by absorbance at 280nm, as calibrated by ELISA (Leinco, St. Louis, MO).
Concentrations are given on a per-nanoparticle basis.
Phosphorylation and dephosphorylation
Phosphorylation was carried out by the addition of the recombinant catalytic subunit of
protein kinase A (PKA, Promega, Madison, WI) and 1mM ATP (EMD Chemicals, San
Diego, CA). For pre-phosphorylation, ~50 units of PKA were used per pmol of Ft. In
DLS and MRI experiments, PKA was added directly from its original stock solution. To
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inhibit PKA activity, we used a peptide PKA inhibitor (Promega). Dephosphorylation
was accomplished using lambda protein phosphatase (PPase, New England Biolabs,
Ipswich, MA), which was diluted in assay buffer and concentrated - 0-fold relative to its
stock solution. Protein phosphorylation states were assayed by electrophoresis on 15%
SDS-PAGE gels (BioRad, Hercules, CA) and staining using the Pro-Q Diamond
phosphoprotein staining kit (Invitrogen). In gel images shown here, lanes have been re-
arranged digitally to align them in the order of data presented in accompanying figures.
DLS
DLS measurements were performed using a DynaPro DLS system (Wyatt Technology,
Santa Barbara, CA) at 25'C. For each sample (2 0pL), a single intensity-weighted value
was used to characterize the average size of all particles in the specimen. This value was
an average of 60 measurements acquired over one minute.
MRI
Samples (60-100 ptL) were arrayed into microtiter plates and placed in a 40-cm-bore
Bruker (Billerica, MA) Avance 4.7 T MRI scanner, equipped with a 10 cm inner
diameter birdcage resonator radiofrequency coil and 26 G/cm triple axis gradients. Un-
used wells of the microtiter plates were filled with phosphate buffered saline, and imag-
ing was performed on a 1.63mm slice through the sample. A T2-weighted spin echo pulse
sequence with multiecho acquisition was used; repetition time (TR) was 4 s, and TE
ranged from 30 to 900 ms, in 30-ms increments. Each acquisition took 8.5 min. Data
matrices of 512 x 128 points were acquired and zero-filled to 1024 x 512 points, where
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the second dimension corresponds to the phase encoding direction. Images were
reconstructed and analyzed using custom routines running in Matlab. Relaxation rates
reported here were calculated by exponential fitting to the image data. Contrast was
adjusted to produce MRI images presented in the figures.
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FIGURE LEGENDS
Figure 1. Ft nanoparticle sensors self-assemble and aggregate in response to PKA
activity. (a) Diagram of the PKA sensor. Ft nanoparticles express either KID or KIX on
their surfaces. When KID is phosphorylated by PKA, the pKID and KIX moieties bind,
causing the nanoparticles to aggregate. Particles also express 3xFLAG groups for
purification and electrostatic stabilization. (b) Coomassie-stained SDS-PAGE gels
showing the composition of FLAG-purified nanoparticles self-assembled from subunits
of HF, LF, FLAG-LF (expected m.w. 23.5 kDA) and either KID-LF (expected m.w. 29
kDA) or KIX-LF (expected m.w. 33.6 kDA). HF and LF appear as a combined band near
20kDa. (c) DLS measurements of relative radius for 3:2 mixtures of KID-NPs and KIX-
NPs incubated for 3.5 hours under the indicated conditions. (1) KIX-NPs and
unphosphorylated KID-NPs; (2) KIX-NPs and pre-phosphorylated KID-NPs; (3)
unphosphorylated sensor with 12.7 units PKA per pmol Ft and 1mM ATP; (4)
unphosphorylated sensor with just ATP; (5) unphosphorylated sensor with PKA, ATP
and 100uM PKA inhibitor; (6) pre-phosphorylated sensor with 1026 units kPPase per
pmol Ft. N=3 for each sample. Insert: mass-weighted size distribution for clusters under
conditions (1) and (2). (d) SDS-PAGE gel stained for phosphoproteins (top) then
coomassie stained (bottom). Lanes correspond to conditions (1)-(6) in (c). In the top gel,
bands shown correspond to the known location of KID-LF; in the bottom gel, KIX-LF
and KID-LF bands are both visible, with the KIX-LF appearing above KID-LF.
Figure 2. Sensors enhance T2 relaxation in MRI in response to PKA activity. (a)
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measurements of the transverse relaxivity (r2) after 2 hours of sensor incubation under the
conditions listed in Fig. 1 (c). For each condition, r2 was calculated by subtracting from
1/T2 the relaxation rate of sensor-free assay buffer containing an identical quantity of
non-Ft species. Insert: T2-weigted MRI image (TE = 210 ms, TR= 4 sec) of wells
containing samples corresponding to conditions (1)-(6). (b) Time course of MRI
relaxation enhancement for sensor incubated with 460 (filled circles), 230 (filled
squares), 115 (open circles) or 0 (open squares) units of PKA, 1mM ATP. Time indicated
is from when PKA was added. N=3 for all data points.
Figure 3. Sensor performance depends on level of functionalization and ratio of partner
particles. (a) Relaxivities (top) and relative radii (bottom) of 3:2 mixtures of KID-NPs
and KIX-NPs expressed with various levels of functional group DNA, as described in the
text. Unphosphorylated sensors (white) and pre-phosphorylated sensors (gray) were
tested at each level of functionalization. (b) Timecourses of transverse relaxation rates
when 60% functionalized KID-NPs and KIX-NPs are mixed at different KID-NP : KIX-
NP ratios, with KID-NPs pre-phosphorylated (top) or unphosphorylated (middle). The
bottom plot shows the difference between the phosphorylated and unphosphorylated
conditions at each ratio. The D:X ratios shown are 2:3 (filled squares), 1:1 (filled circles),
3:2 (open squares) and 3:1 (open circles). N=2 for all data points.
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SUPPLEMENTARY MATERIAL
Amino acid sequences of Ft fusion constructs
Functional domains are highlighted in bold, linkers are highlighted in italic, and LF is in
relular font.
KID-LF:
MGSSCKDLKRLFSGTQISTIAESEDSQESVDSVTDSQKRREILSRRPSYR 50
KILNDLSSDAPGVPRIEEEKSEEETGTSSEFMSSQIRQNYSTDVEAAVNS 100
LVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKM 150
QNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGS 200
ARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFER 250
LTLKHD
KIX-LF:
MSTIPTAAPPSSTGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKD 50
RRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRL 100
HKQGILGNQPALPAGTSSEFMSSQIRQNYSTDVEAAVNSLVNLYLQASYT 150
YLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQ 200
DIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFL 250
ETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD
FLAG-LF:
MDYKDHDGDYKDHDIDYKDDDDKGTSSEFMSSQIRQNYSTDVEAAVNSLV 50
NLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQN 100
QRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSAR 150
TDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLT 200
LKH D
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5. Conclusions and Future Directions
This thesis has described two new protein platforms for the development of
genetically engineered molecular sensors for MRI, and provided a theoretical framework
for a quantitative understanding of the performance characteristics of these and other
sensors. This work represents an important initial step in the development of a new class
of technologies that may some day find widespread use in science and medicine.
However, substantial improvements over our initial prototypes will be needed to reach
this ambitious goal.
BM3h platform: future improvements
Of the two platforms we introduced, the greatest amount of progress has been
demonstrated with BM3h. We showed that our novel methods for directed evolution of
sensor specificity allowed us to create sensors for DA in a relatively straightforward
process. We showed that the resulting sensors could be used to quantify DA release from
cultured cells and image the dynamics of DA transport in the brains of rats exposed to
cocaine. That a protein whose native activity was to catalyze chemical modifications of
fatty acids could, with 9 mutations, be turned into a non-invasive sensor of
neurotransmitter dynamics is remarkable. However, at least two significant challenges
must be addressed to broaden the utility of BM3h-based sensors.
First, the overall (ligand-free) TI relaxivity of BM3h, at ~1.2 mM's-1, is low
relative to synthetic contrast agents. Even in dynamical imaging paradigms (which can
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accept weaker signals because temporal noise is typically lower than spatial noise),
BM3h must be used at concentrations >OuM to elicit detectable changes in MRI signal.
This means it can only sense those targets, such as DA, that are active at or above this
concentration in a given tissue. In the brain, this rules out the use of this sensor to image
glutamate, GABA, glycine and other dilute, local neurotransmitters. Only more
concentrated molecules like DA, serotonin, norepinephrine and melatonin could be
detected.
Several approaches could be tried to improve BM3h's sensitivity as a contrast
agent. Its ligand-free relaxivity depends on the number of unpaired electrons in its heme-
bound metal ion and the exchange rate of water molecules coordinated to this ion. Since
the iron (III) in BM3h normally exists in a mixed 1/2 - 5/2 spin state with spin 1/2
predominating, one may attempt to improve relaxivity by mutating the protein so as to
make its high-spin state more favored. Since this depends on the iron atom's immediate
electronic environment, mutagenesis should be focused around the heme pocket and in
particular on the non-heme ligand C399. Another approach might be to change the metal
contained in BM3h. Porphyrins are available with various other metals, including Mn, Ni
and Co. Because these metals have different d-orbital electron configurations than iron
does, they could possess a higher spin number in BM3h. Transmetallation could be
carried out by refolding denatured BM3h in the presence of the desired metal heme. A
drawback of this approach is that it involves modifying the sensor after it is expressed,
confining its utility to cases where it can be delivered in its intact form rather than as a
genetic construct. Another way to potentially improve relaxivity is to increase water
exchange rates at the open coordination site on the metal ion. This would likely require
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mutations in the protein that are difficult to predict, and would therefore need to be done
through a high-throughput screen. Unfortunately, if the readout of such a screen is MRI,
then the relatively high noise levels of this modality (compared with optical
spectroscopy) would make such a screen inefficient.
A second challenge for BM3h is to show it can work for intracellular sensing.
Many interesting signaling processes occur inside cells, and indeed even intracellular
sensing of DA may find clinical utility in therapies aimed at replacing lost dopaminergic
cells. For BM3h to be a useful intracellular sensor, it must be shown that this protein can
be expressed at high levels in mammalian cells and find sufficient iron heme to be
detectable. It must also be able to sense its target without, through its own interaction
with it, significantly altering its function. A first step in this direction has been taken with
the creation of a mammalian codon-optimized version of BM3h-8C8 and a demonstration
that it can be expressed in mammalian cells to >1% of total cell protein (see appendix A).
BM3h platform: potential applications
BM3h-based sensors could be applied in scientific and clinical imaging in several
formats. As we demonstrated in our initial proof of concept, BM3h could be injected
directly into a site of interest in the brain, where it could sense the dynamics of a target
neurotransmitter. In our proof of concept studies, we co-injected an appropriate quantity
the neurotransmitter and imaged its transport. Direct sensor injections could also be used
experimentally to monitor the release and reuptake of endogenous neurotransmitters, if
such processes can be temporally coupled to imaging (e.g. via electrical stimulation).
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Of course, since a key attraction of MRI is its ability to simultaneously image
large volumes of tissue, it may be desirable to deliver BM3h more widely in the brain and
image target molecule dynamics in a spatially resolved manner. To do this, methods of
delivering the sensor to larger volumes will need to be developed, potentially borrowing
from the body of work on therapeutic delivery to the brain.
If intracellular sensing with BM3h can be demonstrated, BM3h-based sensors
may also find utility as built-in reporters for transplanted cells. For example, much work
has been done to develop dopaminergic cell replacement therapies for Parkinson's
disease . An unfulfilled need in this field has been a way to assay the viability and
performance of transplanted cells. Since the intended activity of such cells is to produce
and release DA, a sensor like BM3h-8C8 incorporated into their genome may be useful in
reporting how well the transplanted cells are performing this function. Intracellular DA is
typically trafficked to vesicles in preparation for release. A way to use a sensor like
BM3h-8C8 could be to express it in the cytoplasm and monitor changes in T 1-weighted
signal after administration of vesicular transporter blockers.
Finally, the gene encoding BM3h could be delivered to endogenous cells using
gene delivery technologies, where it could either serve as an intracellular sensor or be
targeted for secretion to the extracellular space. As both viral and non-viral gene delivery
methods continue to improve, genetically engineered sensors like BM3h-8C8 could find
an increasing range of application in their genetic format.
Ferritin platform: future improvements
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The data presented in this thesis demonstrates the viability of self-assembling
multifunctional Ft nanoparticles to serve as a platform for the development of MRI
sensors. Our initial sensor was targeted at protein kinase A, but our general methodology
could be applied to the making of a variety of future sensors. As in BM3h, however, a
number of challenges must be addressed to broaden the utility of the Ft platform.
Although Ft has already been shown to produce detectable static MRI contrast in-
vivo despite its antiferromagnetic iron oxide core28-30 (which has a weaker magnetic
moment and per-iron relaxivity than do superparamagnetic cores), its utility in sensor
design could be enhanced if relaxivity could be improved by altering its core to a
superparamagnetic state. This has been done successfully through in-vitro iron loading in
a tightly controlled chemical reaction" 3, but since some of the more appealing future
applications of Ft sensors are for intracellular sensing (see next section), it would be
desirable to alter the protein itself to encourage superparamagnetic core formation under
physiological conditions. This might be accomplished by modifying amino acid residues
on Ft's inner surface to favor the nucleation of a particular crystalline structure, as has
114been done with other proteins'4.
To enable Ft-based sensors to be delivered in genetic as well as intact form, it
may also be necessary to introduce an orthogonal system for the formation of
multifunctional molecules that could serve as an aggregating partner for Ft nanoparticles.
With our current constructs, co-transfection of KID-LF and KIX-LF with FLAG-
modified and wild-type subunits would result in the formation of particles expressing
both KID and KIX on their surface, the proximity of which to each other may cause them
to interact within the same nanoparticle rather than with complimentary groups on other
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particles, thus preventing PKA-induced aggregation. Potential starting points for the
development of orthogonal multimeric binding partners include tertameric streptavidin,
trimeric p53, and a variety of dimeric coiled-coil motifs.
Ferritin platform: potential applications
Ft-based sensors may be useful in a variety of applications. In their purified
protein form, sensors such as the one we described could be used to sense intracellular
molecular signaling events after being introduced into cells via methods currently under
development for synthetic nanoparticles (e.g. in combination with cell transfection
reagents or via attachment of membrane-permeating moieties). In the future, genetic
delivery of Ft-based sensors could enable long-term monitoring of intracellular signaling
processes in endogenous tissues or transplanted cells. Unfunctionalized Ft has already
been shown to express and provide static contrast in vivo after viral delivery or genomic
28-30incorporation in transgenic animals -3. This suggests that a sensor such as the one we
described, pending improvements discussed in the previous section, could likewise be
targeted to endogenous tissues and provide functional sensing.
In each aforementioned application, Ft and could BM3h provide complimentary
capabilities, since the former is better suited for imaging macromolecular activities that
occur on longer timescales, while BM3h lends itself best to sensing small molecules. The
fact that BM3h and Ft produce TI and T2 contrast, respectively, suggests that pulse
sequences could be used to distinguish between the signals generated by these probes.
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Appendix A - mammalian expression of BM3h
To set the stage for future work on the use of BM3h-based sensors as genetically
targeted intracellular reporters in mammalian cells and animals, we created a mammalian
codon-optimized version of the BM3h and BM3h-8C8 genes. This was deemed necessary
after a comparison of codon usage between the BM3h gene with the codon frequency
seen in human cells (Fig. la) revealed a high incidence of over-used codons that might
serve as translational bottlenecks. A human codon-optimized sequence was generated
using Gene Designer software (DNA2.0, Menlo Park, CA) with the BM3h amino acid
sequence as an input, and synthesized by Blue Heron (Bothell, WA). The resulting gene
sequence (see appendix C) was cloned into a PCMV-Sport vector (same as the one used
for Ft expression), and transfected into HEK293 cells using the Freestyle293 expression
system (Invitrogen). One day after transfection, cells we supplemented with 0-40uM
hemin to ensure adequate supply of heme for expression and folding of BM3h. The
hexahistidine tag fused to BM3h was then used to purify the protein from crude cell
lysates after four days of expression. It was then run on SDS-PAGE, and its molecular
weight compared to bacterially-expressed BM3h (Fig. lb). The spectrum of mammalian
cell-expressed BM3h looked normal (Fig. 1c). BM3h expression was measured by
performing a CO assay on clarified lysates, and compared to total protein in the lysate
measured by BCA assay (Pierce). Expression levels varied from 0.4% to 1.9% of total
cell protein depending on the level of hemin supplementation during growth (Fig. ld).
However, after supplementation with high levels of hemin, a peak at 420nm was seen in
the CO assay (Fig le), indicating that non-BM3h heme species remain in the cell lysates,
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possibly due to uptake of heme that does not get incorporated into BM3h. A medium
concentration of heme supplement (e.g. l2uM) may offer the highest expression of BM3h
without too much extra uptake of heme by the cells. At this level of supplementation,
around 1.2% of total protein was BM3h. Assuming a typical net protein density of
150mg/ml in living tissues, this would correspond to a tissue BM3h concentration of
~30uM.
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Appendix B - Chemical aggregation of Ferritin
Before embarking on the development of genetically engineered sensors based on Ft, we
confirmed that physical aggregation of Ft could produce T2 contrast changes in MRI. We
used chemical crosslinking via the biotin-streptavidin interaction' to induce controlled
aggregation of horse spleen ferritin (HSF) and monitored the resulting effects on T2
relaxivity in MRI. HSF (pre-loaded with -2,000 iron atoms per particle, Sigma) was
biotinylated at primary amino groups using sulpho-NHS-biotin (Pierce) and purified over
a G-25 desalting column (GE). Protein concentration was measured by absorbance
spectroscopy using a pre-determined titration curve at 400nm. Biotinylated ferritin was
then incubated for lhr with various ratios of streptavidin/ferritin to induce the formation
of aggregates. Mean cluster size was then measured using dynamic light scattering
(DLS), and samples were imaged in 384-well plates using a T2-weighted MRI pulse
sequence. As is apparent from a representative T2-weighted image (Fig 1 a), T2 relaxivity
increases with greater aggregation, leading to greater signal reduction. The relationship
between mean aggregate size and T2 relaxation rate is plotted in Figs lb and lc. A more
than two-fold increase in relaxivity was observed for aggregates of -150nm radius. All
aggregates within this range of apparent sizes remained in solution during the timecourse
of our experiments.
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Appendix C - Gene Sequences
This appendix lists the sequences for all of the genes used in Chapters 2 and 3 of this
thesis. PCMV-Sport and pCWori, the vectors used for mammalian and bacterial
expression, respectively, are also shown. Transcribed genes are in BOLD, with flanking
sequences leading to the restriction sites used for vector cloning shown in normal
typeface.
BM3h
GGATCCATCGATGCTTAGGAGGTCATATGACAATTAAAGAAATGCCTCAGCCAAAAACGT
TTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAAACCGGTTCAAGCTTTGATGA
AAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACGCGCT
ACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACT
TAAGTCAAGCGCTTAAATTTGTACGTGATTTTGCAGGAGACGGGTTATTTACAAGCTGGA
CGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTCAGTCAGCAGG
CAATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGG
AGCGTCTAAATGCAGATGAGCATATTGAAGTACCGGAAGACATGACACGTTTAACGCTTG
ATACGATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTC
ATCCATTTATTACAAGTATGGTCCGTGCACTGGATGAAGCAATGAACAAGCTGCAGCGAG
CAAATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGG
TGATGAACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAAGCGGTGAACAAAGCG
ATGATTTATTAACGCACATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATG
ACGAGAACATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAAACAACAAGTG
GTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGCAG
CAGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGC
TTAAATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGT
TTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCG
ACGAACTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAATTTGGGGAGACGATG
TGGAAGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTA
AACCGTTTGGAAACGGTCAGCGTGCGTGTATCGGTCAGCAGTTCGCTCTTCATGAAGCAA
CGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCATACAAACTACGAGC
TGGATATTAAAGAAACTTTAACGTTAAAACCTGAAGGCTTTGTGGTAAAAGCAAAATCGA
AAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTCATCATCATCATCATCATTAAT
GAATTC
BM3h-8C8
GGATCCATCGATGCTTAGGAGGTCATATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGA
GCTTAAAAATTTACCGTTATTAAACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGA
ATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCT
AATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAAGCGCCTAAATTTGTACG
TGATTTTGCAGGAGACGGGTTATTTACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCG
CATAATATCTTACTTCCAAGCTTCAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATG
GTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGACGAGCATATT
GAAGTACCGGAAGACATGACACGTTTAACGCTTGATACGATTGGTCTTTGCGGCTTTAAC
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TATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATTACAAGTATGGTCCGT
GCACTGGATGAAGCAATGAACAAGCTGCGGCGAGCAAATCCAGACGACCCAGCTTATGAT
GAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATT
ATTGCAGATCGCAAAGCAAGCGGTGAACAAAGCGATGATTTATTAACGCACATGCTAAAC
GGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGAGAACATTCGCTATCAAATTATT
ACATTCTTAGCTGCGGGACACGAAGCAACAAGTGGTCTTTTATCATTTGCGCTGTATTTC
TTAGTGAAAAATCCACATGAATTACAAAAAGCAGCAGAAGAAGCAGCACGAGTTCTAGTA
GATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAAC
GAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATATGCAAAAGAAGATACG
GTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAACTAATGGTTCTGATTCCTCAG
CTTCACCGTGATAAAACAATTTGGGGAGACGATGTGGAAGAGTTCCGTCCAGAGCGTTTT
GAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCG
TGTATCGGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAA
CACTTTGACTTTGAAGATCATACAAACTACGAGCTGGATATTAAAGAAACTTTAACGTTA
AAACCTGAAGGCTTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCT
TCACCTAGCACTCATCATCATCATCATTATTAATGAATTC
BM3h-B7
GGATCCATCGATGCTTAGGAGGTCATATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGA
GCTTAAAAATTTACCGTTATTAAACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGA
ATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCT
AATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAAGCGCCTAAATTTGTACG
TGATCTTGCAGGAGACGGGTTATTTACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAA
TATCTTACTTCCAAGCTTCAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCGC
CGTGCAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGACGAGCATATTGAAGTACCGGAAGACAT
GACACGTTTAACGCTTGATACGATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGA
GATCAGCCTCATCCATTTATTACAAGTATGGTCCGTGCACTGGATGAAGCAATGAACAAGCTGCGG
CGAGCAAATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTG
ATGAACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAAGCGGTGAACAAAGCGATGATTTA
TTAACGCACATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGAGAACATTCG
CTATCAAATTATTACATTCTTAGCTGCGGGACACGAAGCAACAAGTGGTCTTTTATCATTTGCGCTG
TATTTCTTAGTGAAAAATCCACATGAATTACAAAAAGCAGCAGAAGAAGCAGCACGAGTTCTAGTA
GATCCTGTTCCAAGCCACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGAAGCG
CTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGA
GAATATCCTTTAGAAAAAGGCGACGAACTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACA
GTTTGGGGAGACGATGTGGAAGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCA
GCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTGTATCGGTCAGCAGTTCGCTCTTCATGA
AGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCATACAAACTACGAGCT
GGATATTAAAGAAACTTTAACGTTAAAACCTGAAGGCTTTGTGGTAAAAGCAAAATCGAAAAAAAT
TCCGCTTGGCGGTATTCCTTCACCTAGCACTCATCATCATCATCATCATTAATGAATTC
Mammalian codon optimized BMAh
GGTACCACCATGACAATCAAGGAGATGCCTCAGCCTAAAACATTCGGCGAACTGAAGAATCTGCC
GCTTTTGAACACTGACAAACCCGTACAGGCCCTTATGAAGATAGCCGATGAATTGGGTGA
AATTTTTAAGTTTGAGGCGCCCGGGCGCGTAACCAGATATTTGTCCAGTCAGAGGTTGAT
CAAAGAGGCCTGCGATGAGTCTCGCTTTGATAAAAACTTGTCACAGGCACTGAAGTTTGT
CAGAGATTTTGCCGGAGATGGCTTGTTTACGTCCTGGACCCACGAAAAAAACTGGAAGAA
AGCTCATAACATCCTGCTGCCTTCCTTCTCACAACAGGCCATGAAAGGCTACCATGCAAT
GATGGTGGACATCGCGGTCCAGCTGGTGCAGAAATGGGAGAGACTGAATGCCGATGAGCA
CATTGAAGTCCCGGAGGATATGACTCGGCTCACGCTGGATACAATCGGACTGTGTGGCTT
CAATTACCGATTTAACTCATTTTATCGGGATCAGCCTCACCCATTTATCACAAGTATGGT
GAGAGCACTTGACGAGGCAATGAATAAACTGCAGCGCGCTAATCCAGATGATCCGGCATA
TGACGAAAACAAAAGGCAGTTTCAAGAGGACATTAAGGTGATGAACGACTTGGTGGACAA
GATCATCGCAGATCGGAAGGCCTCAGGCGAGCAGTCTGATGATCTCTTGACCCATATGCT
GAATGGGAAAGACCCAGAGACCGGTGAGCCATTGGACGACGAGAATATCAGGTATCAGAT
TATAACTTTTCTGATCGCCGGACACGAGACAACTTCAGGCCTGCTCTCTTTCGCCCTGTA
CTTCCTGGTTAAAAATCCACACGTGCTCCAGAAGGCTGCAGAAGAAGCTGCCAGAGTGCT
TGTAGACCCTGTGCCCTCCTATAAACAAGTGAAGCAGCTTAAGTATGTGGGGATGGTCCT
145
TAATGAGGCACTGCGACTGTGGCCAACTGCGCCCGCCTTCTCTCTGTACGCCAAGGAGGA
TACCGTTCTGGGCGGGGAATATCCTTTGGAGAAAGGCGATGAGCTCATGGTGCTGATCCC
TCAGCTCCATAGAGACAAGACAATTTGGGGCGACGACGTGGAGGAATTCCGGCCTGAACG
GTTTGAGAACCCCTCTGCAATACCACAACACGCGTTTAAACCCTTCGGCAACGGACAGCG
CGCCTGTATAGGCCAACAGTTCGCCCTGCACGAGGCTACCCTCGTGCTCGGTATGATGCT
GAAGCATTTTGACTTTGAGGACCACACAAATTACGAGCTCGACATCAAAGAGACTCTGAC
ACTGAAGCCGGAAGGCTTTGTGGTAAAAGCTAAAAGCAAGAAGATCCCACTGGGAGGAAT
TCCTAGCCCATCTACTCACCACCATCACCACCATTGATCTAGA
Mammalian codon optimized BM3h-8C8
GGTACCACCATGACAATCAAGGAGATGCCTCAGCCTAAAACATTCGGCGAACTGAAGAATCTGCCG
CTTTTGAACACTGACAAACCCGTACAGGCCCTTATGAAGATAGCCGATGAATTGGGTGAAATT
TTTAAGTTTGAGGCGCCCGGGCGCGTAACCAGATATTTGTCCAGTCAGAGGTTGATCAAA
GAGGCCTGCGATGAGTCTCGCTTTGATAAAAACTTGTCACAGGCACCGAAGTTTGTCAGA
GATTTTGCCGGAGATGGCTTGTTTACGTCCTGGACCCACGAAAAAAACTGGAAGAAAGCT
CATAACATCCTGCTGCCTTCCTTCTCACAACAGGCCATGAAAGGCTACCATGCAATGATG
GTGGACATCGCGGTCCAGCTGGTGCAGAAATGGGAGAGACTGAATGCCGATGAGCACATT
GAAGTCCCGGAGGATATGACTCGGCTCACGCTGGATACAATCGGACTGTGTGGCTTCAAT
TACCGATTTAACTCATTTTATCGGGATCAGCCTCACCCATTTATCACAAGTATGGTGAGA
GCACTTGACGAGGCAATGAATAAACTGCGGCGCGCTAATCCAGATGATCCGGCATATGAC
GAAAACAAAAGGCAGTTTCAAGAGGACATTAAGGTGATGAACGACTTGGTGGACAAGATC
ATCGCAGATCGGAAGGCCTCAGGCGAGCAGTCTGATGATCTCTTGACCCATATGCTGAAT
GGGAAAGACCCAGAGACCGGTGAGCCATTGGACGACGAGAATATCAGGTATCAGATTATA
ACTTTTCTGGCCGCCGGACACGAGGCAACTTCAGGCCTGCTCTCTTTCGCCCTGTACTTC
CTGGTTAAAAATCCACACGAGCTCCAGAAGGCTGCAGAAGAAGCTGCCAGAGTGCTTGTA
GACCCTGTGCCCTCCTATAAACAAGTGAAGCAGCTTAAGTATGTGGGGATGGTCCTTAAT
GAGGCACTGCGACTGTGGCCAACTGCGCCCGCCTTCTCTCTGTACGCCAAGGAGGATACC
GTTCTGGGCGGGGAATATCCTTTGGAGAAAGGCGATGAGCTCATGGTGCTGATCCCTCAG
CTCCATAGAGACAAGACAATTTGGGGCGACGACGTGGAGGAATTCCGGCCTGAACGGTTT
GAGAACCCCTCTGCAATACCACAACACGCGTTTAAACCCTTCGGCAACGGACAGCGCGCC
TGTATAGGCCAACAGTTCGCCCTGCACGAGGCTACCCTCGTGCTCGGTATGATGCTGAAG
CATTTTGACTTTGAGGACCACACAAATTACGAGCTCGACATCAAAGAGACTCTGACACTG
AAGCCGGAAGGCTTTGTGGTAAAAGCTAAAAGCAAGAAGATCCCACTGGGAGGAATTCCT
AGCCCATCTACTCACCACCATCACCACCATTGATCTAGA
HF
GGTACCGAGCTCGGATCCAGTACCCTTCACCATGGAATTCATGACGACCGCGTCCACCTCGCAGGTGC
GCCAGAACTACCACCAGGACTCAGAGGCCGCCATCAACCGCCAGATCAACCTGGAGCTCTACGCC
TCCTACGTTTACCTGTCCATGTCTTACTACTTTGACCGCGATGATGTGGCTTTGAAGAACTTTGCCA
AATACTTTCTTCACCAATCTCATGAGGAGAGGGAACATGCTGAGAAACTGATGAAGCTGCAGAACC
AACGAGGTGGCCGAATCTTCCTTCAGGATATCAAGAAACCAGACTGTGATGACTGGGAGAGCGGG
CTGAATGCAATGGAGTGTGCATTACATTTGGAAAAAAATGTGAATCAGTCACTACTGGAACTGCAC
AAACTGGCCACTGACAAAAATGACCCCCATTTGTGTGACTTCATTGAGACACATTACCTGAATGAG
CAGGTGAAAGCCATCAAAGAATTGGGTGACCACGTGACCAACTTGCGCAAGATGGGAGCGCCCGA
ATCTGGCTTGGCGGAATATCTCTTTGACAAGCACACCCTGGGAGACAGTGATAATGAAAGCTAA
AAGGGTCAAGACAATTCTGCAGA TATCCAGCACAGTGGCGGCC GCTCGAGTCTAGA
LF
GGTACCGAGCTCGGATCCAGTACCCTTCACCATGGAATTCATGAGCTCCCAGATTCGTCAGAATTATT
CCACCGACGTGGAGGCAGCCGTCAACAGCCTGGTCAATTTGTACCTGCAGGCCTCCTACACCTACC
TCTCTCTGGGCTTCTATTTCGACCGCGATGATGTGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCG
AATTGGCCGAGGAGAAGCGCGAGGGCTACGAGCGTCTCCTGAAGATGCAAAACCAGCGTGGCGGC
CGCGCTCTCTTCCAGGACATCAAGAAGCCAGCTGAAGATGAGTGGGGTAAAACCCCAGACGCCAT
146
GAAAGCTGCCATGGCCCTGGAGAAAAAGCTGAACCAGGCCCTTTTGGATCTTCATGCCCTGGGTTC
TGCCCGCACGGACCCCCATCTCTGTGACTTCCTGGAGACTCACTTCCTAGATGAGGAAGTGAAG
CTTATCAAGAAGATGGGTGACCACCTGACCAACCTCCACAGGCTGGGTGGCCCGGAGGCT
GGGCTGGGCGAGTATCTCTTCGAAAGGCTCACTCTCAAGCACGACTAA AGGGTCAAGAC
AATTCTGC AGATATCCAGCACAGTGGCGGCC GCTCGAGTCTAGA
FLAG-LF
GGTACCGAGCTCGGATCCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACAT
CGATTACAAGGATGACGATGACAAGGGAACCAGCAGCGAATTCATGAGCTCCCAGATTCG
TCAGAATTATTCCACCGACGTGGAGGCAGCCGTCAACAGCCTGGTCAATTTGTACCTGCA
GGCCTCCTACACCTACCTCTCTCTGGGCTTCTATTTCGACCGCGATGATGTGGCTCTGGA
AGGCGTGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAGCGCGAGGGCTACGAGCGTCT
CCTGAAGATGCAAAACCAGCGTGGCGGCCGCGCTCTCTTCCAGGACATCAAGAAGCCAGC
TGAAGATGAGTGGGGTAAAACCCCAGACGCCATGAAAGCTGCCATGGCCCTGGAGAAAAA
GCTGAACCAGGCCCTTTTGGATCTTCATGCCCTGGGTTCTGCCCGCACGGACCCCCATCT
CTGTGACTTCCTGGAGACTCACTTCCTAGATGAGGAAGTGAAGCTTATCAAGAAGATGGG
TGACCACCTGACCAACCTCCACAGGCTGGGTGGCCCGGAGGCTGGGCTGGGCGAGTATCT
CTTCGAAAGGCTCACTCTCAAGCACGACTAA AGGGTCAAGAC AATTCTGC
AGATATCCAGCACAGTGGCGGCC GCTCGAGTCTAGA
KID-LF
GGTACCGAGCTCGGATCCACCATGGGTTCTTCCTGTAAGGACTTAAAAAGACTTTTCTCCGGAACTC
AGATTTCAACTATTGCAGAAAGTGAAGATTCACAGGAGTCTGTGGATAGTGTAACTGATTCCCAAA
AACGAAGGGAAATCCTTTCAAGGAGGCCTTCCTACAGGAAAATTTTGAATGACTTATCTTCTGATG
CACCAGGGGTGCCAAGGATTGAAGAAGAAAAATCAGAAGAAGAGACTGGAACCAGCAGCGAA
TTCATGAGCTCCCAGATTCGTCAGAATTATTCCACCGACGTGGAGGCAGCCGTCAACAGC
CTGGTCAATTTGTACCTGCAGGCCTCCTACACCTACCTCTCTCTGGGCTTCTATTTCGAC
CGCGATGATGTGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAG
CGCGAGGGCTACGAGCGTCTCCTGAAGATGCAAAACCAGCGTGGCGGCCGCGCTCTCTTC
CAGGACATCAAGAAGCCAGCTGAAGATGAGTGGGGTAAAACCCCAGACGCCATGAAAGCT
GCCATGGCCCTGGAGAAAAAGCTGAACCAGGCCCTTTTGGATCTTCATGCCCTGGGTTCT
GCCCGCACGGACCCCCATCTCTGTGACTTCCTGGAGACTCACTTCCTAGATGAGGAAGTG
AAGCTTATCAAGAAGATGGGTGACCACCTGACCAACCTCCACAGGCTGGGTGGCCCGGAG
GCTGGGCTGGGCGAGTATCTCTTCGAAAGGCTCACTCTCAAGCACGACTAA AGGGTCAAGAC
AATTCTGC AGATATCCAGCACAGTGGCGGCC GCTCGAGTCTAGA
KIX-LF
GGTACCGAGCTCGGATCCACCTGAGCACGATACCTACAGCAGCGCCTCCTTCCAGCACTGGTGTTCG
AAAAGGCTGGCATGAACATGTGACTCAGGACCTACGGAGTCATCTAGTCCATAAACTCGTTCAAGC
CATCTTCCCAACTCCAGACCCTGCAGCTCTGAAAGATCGCCGCATGGAGAACCTGGTTGCCTATGC
TAAGAAAGTGGAGGGAGACATGTATGAGTCTGCTAATAGCAGGGATGAATACTATCATTTA
TTAGCAGAGAAAATCTATAAAATACAAAAAGAACTAGAAGAAAAGCGGAGGTCACGTTTA
CATAAGCAAGGCATCCTGGGTAACCAGCCAGCTTTACCAGCGGGAACCAGCAGCGAATTC
ATGAGCTCCCAGATTCGTCAGAATTATTCCACCGACGTGGAGGCAGCCGTCAACAGCCTG
GTCAATTTGTACCTGCAGGCCTCCTACACCTACCTCTCTCTGGGCTTCTATTTCGACCGC
GATGATGTGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAGCGC
GAGGGCTACGAGCGTCTCCTGAAGATGCAAAACCAGCGTGGCGGCCGCGCTCTCTTCCAG
GACATCAAGAAGCCAGCTGAAGATGAGTGGGGTAAAACCCCAGACGCCATGAAAGCTGCC
ATGGCCCTGGAGAAAAAGCTGAACCAGGCCCTTTTGGATCTTCATGCCCTGGGTTCTGCC
CGCACGGACCCCCATCTCTGTGACTTCCTGGAGACTCACTTCCTAGATGAGGAAGTGAAG
CTTATCAAGAAGATGGGTGACCACCTGACCAACCTCCACAGGCTGGGTGGCCCGGAGGCT
GGGCTGGGCGAGTATCTCTTCGAAAGGCTCACTCTCAAGCACGACTAA AGGGTCAAGAC
AATTCTGC AGATATCCAGCACAGTGGCGGCC GCTCGAGTCTAGA
147
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GAATTCATCGATGATAAGCTGTCAAACATGAGCAGATCTGAGCCCGCCTAATGAGCGGGC
TTTTTTTTCAGATCTGCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTT
AATGTCATGATAATAATGGTTTCTTAGCGTCAAAGCAACCATAGTACGCGCCCTGTAGCG
GCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCG
CCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC
CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACC
TCGACCCCAAAAAACTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGA
CGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAA
CTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGA
TTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACA
AAATATTAACGTTTACAATTTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTA
TTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGAT
AAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGA
AAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCA
ACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
TTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCG
GTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGC
ATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATA
ACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTT
TGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAG
CCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCA
AACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGG
AGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTG
CTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAG
ATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATG
AACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAG
ACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGA
TCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGT
TCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTC
TGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGC
CGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATAC
CAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCAC
CGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGT
CGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCT
148
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GAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGAT
ACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGT
ATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACG
CCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGT
GATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGT
TCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTG
TGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCG
AGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTA
CGCATCTGTGCGGTATTTCACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGA
TGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCG
CCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCC
GCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCA
TCACCGAAACGCGCGAGGCAGAACGCCATCAAAAATAATTCGCGTCTGGCCTTCCTGTAG
CCAGCTTTCATCAACATTAAATGTGAGCGAGTAACAACCCGTCGGATTCTCCGTGGGAAC
AAACGGCGGATTGACCGTAATGGGATAGGTTACGTTGGTGTAGATGGGCGCATCGTAACC
GTGCATCTGCCAGTTTGAGGGGACGACGACAGTATCGGCCTCAGGAAGATCGCACTCCAG
CCAGCTTTCCGGCACCGCTTCTGGTGCCGGAAACCAGGCAAAGCGCCATTCGCCATTCAG
GCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACG
ACGTTGTAAAACGACGGCCAGTGAATCCGTAATCATGGTCATAGCTGTTTCCTGTGTGAA
ATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCT
GGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCG
GTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGA
TTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCC
AGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCG
GTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGACTCGGTAATG
GCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATG
CCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTTCC
CGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGC
AGACGCGCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAAT
GCGACCAGATGCTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTG
ATGGGTGTCTGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGCAGGCAGCTTCC
ACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACTGACGCGTTGC
GCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTACCATCGAC
ACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGAC
GGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCC
AGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTT
TCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAA
GAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTG
AATTGACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATG
GTGTCCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT
GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATA
ATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGGATCGATCCATCGATG
AGCTTACTCCCCATCCCCCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTG
TGAGCGGATAACAATTTCACACAGGAAACAGGATCAGCTTACTCCCCATCCCCCTGTTGA
CAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGG
AAACAGGATCC
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TCTAGAGGATCCCTCGAGGGGCCCAAGCTTACGCGTGCATGCGACGTCATAGCTCTCTCC
CTATAGTGAGTCGTATTATAAGCTAGCTTGGGATCTTTGTGAAGGAACCTTACTTCTGTG
GTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAAT
TTTTAAGTGTATAATGTGTTAAACTAGCTGCATATGCTTGCTGCTTGAGAGTTTTGCTTA
CTGAGTATGATTTATGAAAATATTATACACAGGAGCTAGTGATTCTAATTGTTTGTGTAT
TTTAGATTCACAGTCCCAAGGCTCATTTCAGGCCCCTCAGTCCTCACAGTCTGTTCATGA
TCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAG
CTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTT
CACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCG
ATCCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGCTGGCGT
AATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAA
TGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGA
CCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCG
CCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGAT
TTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTG
GGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATA
GTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATT
TATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAAT
TTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTCAGGTGGCACTTTTCGGGGAA
ATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCA
TGCCAGGTCTTGGACTGGTGAGAACGGCTTGCTCGGCAGCTTCGATGTGTGCTGGAGGGA
GAATAAAGGTCTAAGATGTGCGATAGAGGGAAGTCGCATTGAATTATGTGCTGTGTAGGG
ATCGCTGGTATCAAATATGTGTGCCCACCCCTGGCATGAGACAATAACCCTGATAAATGC
TTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTC
CCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAA
AAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCG
GTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAG
TTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCC
GCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTA
CGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTG
CGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACA
ACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATAC
CAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTAT
TAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGG
ATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATA
AATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTA
AGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
ATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAG
TTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGG
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TGAAGATCCTTTTTGATAATCTCATGCCATAACTTCGTATAATGTATGCTATACGAAGTT
ATGGCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAG
AAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAA
CAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTT
TTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGC
CGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAA
TCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAA
GACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGC
CCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAA
GCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAA
CAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCG
GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCC
TATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTG
CTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTG
AGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGG
AAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAAT
GCAGAGCTTGCAATTCGCGCGTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTC
TCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCA
CATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCT
ATAAAAATAGGCGTGATACGAGGCCCTTTCACTCATTAGGCACCCCAGGCTTTACACTTT
ATAGCTTCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAA
CAGCATCGTGCAGGTCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA
CGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGAC
TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTG
GCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT
AGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCG
GTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTG
GCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAAT
GGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCA
GATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATC
CAGCCTCCGGACTCTAGCCTAGGCTTTTGCAAAAAGCTATTTAGGTGACACTATAGAAGG
TACGCCTGCAGGTACC
'Li M et al. Organization of inorganic nanoparticles using biotin-streptavidin connectors. Chem Mater. 11,
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